Terminal2 · Diagnosis Card #00

[Diagnosis Name]

A hospice-first, evidence-based clinical reference for clinicians, families, and patients navigating this diagnosis at end of life. Built for the team beside the bed.

S01 Everyone

What Is It

Severe rheumatoid arthritis and systemic lupus erythematosus at end of life — two autoimmune diseases that share enough end-stage features to warrant combined coverage with disease-specific distinctions throughout.

RA Prevalence (US)
~1.5 M
Approximately 0.5–1% of the adult population; 2–3× more common in women; peak incidence at ages 30–60; symmetric synovitis of small joints, wrists, elbows, knees, and cervical spine.[1]
SLE Prevalence (US)
~300 K
Approximately 0.06–0.2% of adults; 9:1 female-to-male ratio; 3:1 Black-to-white incidence; peak onset 15–45 years; disproportionately severe in Black, Asian, and Hispanic women.[2]
RA Excess Mortality
SMR 1.5–2.0
50–100% excess mortality versus the general population; leading causes: cardiovascular disease (40%), infections (20–25%), malignancy (15%); median 10–15 life-years lost in severe RA.[3]
SLE Excess Mortality
SMR ≥2.4
Black women with SLE: SMR >3.0; leading causes: CVD, infection, lupus nephritis/ESRD, NPSLE; up to 20 life-years lost in severe juvenile-onset SLE; 15–30 years of disease before hospice eligibility.[4]

Severe rheumatoid arthritis and systemic lupus erythematosus are chronic systemic autoimmune diseases that share enough end-stage clinical features to warrant combined coverage in hospice. RA is characterized by symmetric inflammatory synovitis that preferentially destroys the small joints of the hands and feet, the wrists, the elbows, the knees, and — critically for hospice positioning — the cervical spine.[1] SLE is a multi-system autoimmune disease driven by autoantibody-mediated immune complex deposition affecting the kidneys, heart, lungs, brain, skin, joints, and blood — producing the most diverse end-organ complication spectrum of any autoimmune disease.[2] Together, these two diseases account for the majority of end-stage inflammatory arthritis and systemic autoimmune disease encountered in hospice care. The patient arriving at hospice from RA or SLE has typically lived with their disease for 15–30 years before reaching the end-stage complication burden that triggers hospice eligibility.[5]

The medication burden of decades of RA/SLE treatment is paradoxically both the reason the patient is alive and the reason they are dying. The corticosteroids — prednisone at doses from 5 mg/day maintenance to 60 mg/day acute flare, taken continuously for decades — produce hypothalamic-pituitary-adrenal (HPA) axis suppression creating the adrenal insufficiency that requires the most careful tapering protocol in all of rheumatological medicine; osteoporosis producing vertebral compression fractures and hip fractures; avascular necrosis (AVN) of the femoral heads and humeral heads; Cushingoid body habitus (moon face, central obesity, thin skin, easy bruising, striae) that has altered the patient's appearance for years; cataracts; glaucoma; and profound immunosuppression.[6] The disease-modifying antirheumatic drugs (DMARDs) carry their own cumulative toxicity: methotrexate produces hepatic fibrosis, bone marrow suppression, and pulmonary toxicity; cyclophosphamide produces hemorrhagic cystitis, bladder malignancy, and gonadal failure; mycophenolate mofetil causes GI toxicity and immunosuppression.[7] The biologics — TNF inhibitors (adalimumab, etanercept, infliximab), rituximab, belimumab — increase the risk of serious bacterial infections, reactivation tuberculosis, serious fungal infections, and Pneumocystis jirovecii pneumonia (PCP).[8] The accumulated organ toxicity of these decades of treatment constitutes a specific and identifiable clinical burden at hospice enrollment.

SLE produces end-stage complications that span virtually every organ system. Lupus nephritis — occurring in approximately 40–50% of SLE patients — is the most common cause of death in SLE; Classes III (focal proliferative), IV (diffuse proliferative), and V (membranous) nephritis define the clinical spectrum, with Class III–IV nephritis most frequently progressing to ESRD requiring the Card #47 dialysis withdrawal framework.[9] Neuropsychiatric SLE (NPSLE) produces seizures (10–15% of SLE patients), stroke from cerebral vasculitis and antiphospholipid syndrome (APS)-related thrombosis, cognitive impairment ("lupus fog"), psychosis, chorea, myelitis, and optic neuritis.[10] Serositis — pericarditis, pleuritis, and peritonitis — produces the pain that responds specifically to NSAIDs and corticosteroids.[11] Cardiovascular SLE includes Libman-Sacks endocarditis (sterile valvular vegetations producing valve dysfunction and embolic risk), premature coronary artery disease from inflammation-driven atherosclerosis, and cardiomyopathy from myocarditis.[12] Pulmonary SLE includes interstitial lung disease, pulmonary hypertension (applying the Card #45 framework), acute lupus pneumonitis, and diffuse alveolar hemorrhage (DAH) — the latter two being the most acutely life-threatening pulmonary manifestations.[13]

Antiphospholipid syndrome (APS) complicates approximately 30–40% of SLE patients and a minority of RA patients. APS is characterized by antiphospholipid antibodies (anti-cardiolipin, anti-beta2 glycoprotein I, lupus anticoagulant) that produce a hypercoagulable state manifesting as arterial thrombosis (stroke, MI, digital ischemia), venous thrombosis (DVT, PE, cerebral venous sinus thrombosis), and recurrent pregnancy losses.[14] Catastrophic APS (CAPS) — simultaneous thromboses in multiple organ systems (brain, kidneys, lungs, skin, adrenals) — carries approximately 50% mortality even with aggressive treatment.[15] The accelerated atherosclerosis of both RA and SLE is driven by chronic systemic inflammation increasing oxidative LDL, endothelial dysfunction from immune complex deposition, and corticosteroid-driven dyslipidemia; cardiovascular disease is the leading cause of death in both diseases, arriving 10–15 years earlier than in the general population.[3][12]

🧭 Clinical Framing — The Three Simultaneous Forces

Severe RA and SLE at hospice represent the terminal convergence of three simultaneous forces: (1) the ongoing inflammatory disease that continues to damage joints, kidneys, heart, lungs, and nervous system despite maximal tolerated treatment; (2) the accumulated structural damage from decades of that inflammatory disease — the cartilage loss, the bone erosion, the nephron loss, the myocardial fibrosis, the periarticular changes that produce joint contractures; and (3) the pharmacological toxicity of the immunosuppressive regimen that controlled the inflammation well enough to extend survival but that produced the avascular necrosis, osteoporosis, infections, malignancies, and organ damage that constitute the secondary disease burden.[5] These three forces cannot be disentangled at end stage — the patient's symptoms are produced by all three simultaneously, and every clinical decision (continue the methotrexate? taper the prednisone? treat the PCP? anticoagulate for APS?) requires weighing the interactions between all three.

From the Field
Waldo Rios, NP
Hospice NP · 12+ Years
"I walked into a severe RA home — patient was 72, had RA since she was 38. Prednisone for 31 years. AVN in both hips, right one replaced twelve years ago, left one too risky now given her cardiac status. Both hands locked in fixed flexion — ten years of progressive contracture — the web spaces macerated because nobody had put gauze padding in there. She had a documented C1-C2 atlanto-axial subluxation on a cervical MRI from three years ago. It was not in the hospice intake notes. The physical therapist had been adjusting her neck positioning. The aide had been doing morning care with a chin-to-chest traction she was too stoic to complain about. She'd had two PCP episodes in four years — the second one put her in the ICU for eight days — and nobody had written PCP prophylaxis after the second episode. I pulled the cervical imaging before I touched her. I called the AAI restriction to every caregiver in that house before anyone touched her again. I wrote the TMP-SMX prescription. I calculated the minimum physiological prednisone dose. I padded the web spaces. And then I sat down with this woman — 72 years old, RA since 38 — and asked: 'What does a good day look like for you now? What are the most important things in the time we have together?' That is what it means to be the first clinician who walks into an RA home and reads the chart before reading the disease."
— Waldo, NP · Terminal2
S02Clinician

How It's Diagnosed

RA and SLE diagnoses are established before hospice enrollment. This section covers the diagnostic criteria, clinical staging, and the specific documentation the hospice clinician must review and verify at enrollment.

RA Diagnostic Criteria & Hospice Documentation
Guideline

2010 ACR/EULAR Classification Criteria for RA — the established diagnostic framework scored across four domains:[16]

  • Joint involvement: Number and size of involved joints (1 large joint = 0 points; ≥10 small joints = 5 points); the end-stage RA patient will have extensive polyarticular disease
  • Serology: Rheumatoid factor (RF) and anti-citrullinated protein antibody (ACPA/anti-CCP); seropositivity status matters at hospice — anti-CCP positive RA carries higher risk of extra-articular disease (rheumatoid nodules, RA-ILD, vasculitis) and more erosive joint destruction than seronegative RA[17]
  • Acute-phase reactants: ESR and CRP document historical disease activity burden
  • Symptom duration: ≥6 weeks required; end-stage patients have decades of documented disease
  • DAS28 (Disease Activity Score-28): Historical trend documents cumulative disease activity burden
  • Van der Heijde erosion score / Sharp score: Serial radiographs document structural joint damage severity[18]
SLE Diagnostic Criteria & Antibody Profile
Guideline

2019 EULAR/ACR SLE Classification Criteria — domain-based scoring system with positive ANA as mandatory entry criterion:[19]

  • Domains scored: Constitutional, hematologic, neuropsychiatric, mucocutaneous, serosal, musculoskeletal, and renal manifestations
  • Anti-dsDNA: Most specific for SLE; titers correlate with disease activity — rising anti-dsDNA with falling complement C3/C4 heralds a lupus flare[20]
  • Anti-Sm (anti-Smith): Highly specific for SLE; more common in Black women with SLE
  • Anti-Ro/SSA and anti-La/SSB: Associated with neonatal lupus and Sjögren's overlap
  • Antiphospholipid antibodies: Anti-cardiolipin, anti-beta2GPI, lupus anticoagulant — determine APS presence and anticoagulation requirement[14]
  • SLEDAI (SLE Disease Activity Index): Quantifies active disease across organ domains[21]
RA — What to Document at Hospice Enrollment
Critical
  • Joint contracture inventory: Which joints, degree of fixed deformity, functional impact, pressure injury risk at each contracture site — swan neck deformities, boutonnière deformities, ulnar deviation at MCPs, wrist subluxation, elbow and hip/knee flexion contractures[22]
  • Cervical spine status — MOST URGENT: Has atlanto-axial subluxation been assessed? Review MRI of cervical spine. If C1-C2 distance >3 mm, document AAI restriction immediately and communicate to every caregiver before any care is delivered[23]
  • Respiratory status: Is RA-ILD present? CT chest findings? If interstitial lung disease is present, apply the Card #43 framework with RA-specific modifications[24]
  • Cardiovascular status: RA-associated accelerated atherosclerosis, known CAD, pericardial effusion, heart failure class
  • Corticosteroid history: Current prednisone dose, duration of use, minimum physiological replacement dose calculated (5–7.5 mg/day)[6]
  • PCP prophylaxis status: Is TMP-SMX or dapsone prescribed? If not, start at enrollment[25]
SLE — What to Document at Hospice Enrollment
Critical
  • Current organ involvement inventory: Nephritis class if documented; NPSLE manifestations (seizures, psychosis, cognitive impairment); serositis (pericarditis, pleuritis); pulmonary involvement; cardiovascular involvement[9]
  • Renal function — eGFR and dialysis status: If ESRD or dialysis are present, apply the Card #47 dialysis withdrawal framework; lupus anticoagulant complicates anticoagulation management in an ESRD patient on hemodialysis[26]
  • APS status and anticoagulation: Are antiphospholipid antibodies positive? Is the patient on warfarin? Document the target INR and reassess the comfort-benefit of ongoing anticoagulation against bleeding risk[14]
  • NPSLE seizure management: Is the patient on anticonvulsants? Document current regimen; do not discontinue — seizure recurrence produces significant distress[10]
  • Current immunosuppressive regimen: Each agent, its specific indication, and its comfort-benefit at end stage
  • PCP prophylaxis and corticosteroid minimum dose: Same safety priorities as RA[25]
The Critical Medication Inventory at Enrollment
Safety

The medication list of an RA/SLE patient at hospice enrollment is among the longest in all of hospice. The systematic medication review must:[7]

  • Corticosteroids: Identify all corticosteroids, their doses, and duration; calculate the minimum physiological replacement dose (prednisone 5–7.5 mg/day equivalent); do NOT stop corticosteroids in a patient on them for >3 months without calculating this threshold[6]
  • DMARDs and biologics: Identify each agent; assess comfort-benefit; methotrexate, mycophenolate, TNF inhibitors, rituximab — each requires individual reassessment
  • PCP prophylaxis: TMP-SMX SS daily or dapsone 100 mg daily — if not present, start at enrollment in any patient on significant immunosuppression[25]
  • Anticoagulation: For APS — assess ongoing indication against bleeding risk; document the decision
  • NSAIDs: Assess renal safety; absolute contraindication if lupus nephritis eGFR <30[27]
  • PPI for gastroprotection: Continue in patients on long-term NSAIDs and corticosteroids
  • Bisphosphonates: For steroid-induced osteoporosis — apply the comfort-benefit framework from Card #52
Hospice Eligibility Criteria — RA and SLE
Expert Consensus

RA/SLE patients meet hospice eligibility through one or more of these end-stage complication pathways:[5]

  • ESRD from lupus nephritis: Requiring the Card #47 framework for dialysis decision-making; Class III–IV nephritis that progressed despite mycophenolate and rituximab
  • Class III–IV heart failure: From lupus or RA cardiomyopathy, or accelerated atherosclerosis-driven coronary disease
  • Recurrent life-threatening infections: PCP or other opportunistic infections despite prophylaxis, from cumulative immunosuppression[8]
  • Severe functional decline: PPS below 40% from joint contractures and irreversible organ damage
  • RA-ILD progression: Interstitial lung disease requiring supplemental oxygen with progressive restrictive physiology (apply Card #43 framework)[24]
  • End-stage complications unresponsive to maximally tolerated immune modulation: Disease that continues to progress despite all available treatment options

💡 For Families

Your loved one's rheumatoid arthritis or lupus was diagnosed years — often decades — ago. The diagnosis is not new. What has changed is that the long-term effects of the disease and the medications used to control it have accumulated to the point where comfort-focused care is now the most appropriate approach. The hospice team needs to understand the full history of your loved one's disease: every medication they have taken, every complication they have experienced, every joint that has been affected, and every organ that has been involved. This history is not just medical background — it is the map the hospice team uses to keep your loved one safe and comfortable. If you have records from the rheumatologist, medication lists, imaging reports, or notes about the cervical spine, please share them at enrollment. They are directly relevant to safe care.[5]

S03Everyone

Causes & Risk Factors

RA and SLE pathogenesis, the autoimmune mechanisms that produce decades of joint destruction and multi-organ damage, and the clinical relevance for end-of-life management.

RA Pathogenesis — The Autoimmune Mechanism and Joint Destruction
Review

The autoimmune cascade that drives RA joint destruction:

  • Immune cell infiltration: Activated T-cells and B-cells infiltrate the synovial membrane, producing the chronic synovitis that is the hallmark of RA[28]
  • Synoviocyte activation: Synovial lining cells produce matrix metalloproteinases (MMPs) that enzymatically digest articular cartilage; activated osteoclasts erode subchondral bone
  • Cytokine cascade: TNF-alpha, IL-1, IL-6, and IL-17 maintain the inflammatory cascade — these are the targets of biologic DMARDs (anti-TNF agents, tocilizumab, secukinumab)[29]
  • Pannus formation: The invasive synovial tissue (pannus) grows over and destroys the articular surface; years of pannus invasion produce the cartilage loss, bone erosion, and periarticular soft tissue changes of end-stage RA
  • Genetic susceptibility: HLA-DR4 (shared epitope) — present in ~60–70% of seropositive RA; HLA-DRB1 alleles determine disease severity and extra-articular risk[30]
  • Environmental triggers: Cigarette smoking (strongest modifiable risk factor — RR ~1.5–2.0 for seropositive RA; also worsens RA-ILD); periodontal disease (Porphyromonas gingivalis citrullination); silica dust exposure[31]
SLE Pathogenesis — Immune Complex Deposition and Multi-Organ Damage
Review

The autoimmune mechanism in SLE and its systemic consequences:

  • Defective apoptotic clearance: Impaired clearance of cellular debris — DNA, nucleosomes, and other intracellular antigens released from apoptotic cells — activates autoreactive B-cells and T-cells[32]
  • Autoantibody production: Anti-dsDNA, anti-Sm, and antiphospholipid antibodies form pathogenic immune complexes that deposit in end-organ tissues
  • Renal deposition: Immune complex deposition in glomeruli produces complement activation and neutrophil recruitment causing lupus nephritis — the mechanism behind the most common cause of death in SLE[9]
  • Neuropsychiatric damage: Immune complex deposition, cerebral vasculitis, and APS-related thrombosis produce NPSLE manifestations — seizures, stroke, psychosis, cognitive impairment[10]
  • Cardiac damage: Immune complex deposition produces Libman-Sacks endocarditis and myocarditis; chronic inflammation drives accelerated atherosclerosis[12]
  • Genetic susceptibility: HLA-DR2 and HLA-DR3; complement deficiencies (C1q, C2, C4); ITGAM, STAT4, IRF5 gene variants; familial concordance 24–69% in monozygotic twins[33]
  • Environmental triggers: Ultraviolet light (triggers flares via increased apoptosis and autoantigen exposure); Epstein-Barr virus infection; hormonal factors (estrogen potentiates B-cell activation — explains the 9:1 female predominance)[34]
End-Stage RA Joint Contractures — The Positioning Crisis
Grade A

The joint destruction from years of pannus invasion produces the specific fixed deformities of end-stage RA that the hospice clinician must recognize and manage:[22]

  • Hand deformities: Swan neck deformities (PIP hyperextension with DIP flexion); boutonnière deformities (PIP flexion with DIP hyperextension); ulnar deviation of the MCP joints; volar subluxation of the wrists — the web spaces of contracted hands develop pressure injuries, maceration, and fungal infection from skin-on-skin contact[35]
  • Upper extremity: Elbow flexion contractures limiting positioning options; shoulder adhesive capsulitis preventing arm abduction for hygiene and positioning
  • Lower extremity: Hip and knee flexion contractures that make standard supine positioning impossible; the patient cannot lie flat, requiring positioning wedges under flexed knees and lateral positioning protocols[36]
  • Cervical spine — ATLANTO-AXIAL SUBLUXATION: Pannus at the C1-C2 articulation erodes the transverse ligament stabilizing the odontoid process; C1-C2 distance >3 mm on lateral radiograph or MRI indicates subluxation; neck flexion can produce acute spinal cord compression with tetraplegia or death — the most dangerous positioning issue in rheumatological hospice[23]
Health Disparities in SLE — Clinical and Structural Inequity
Grade B

The health disparity dimensions of SLE that every hospice clinician must understand:[37]

  • Black women with SLE: Standardized mortality ratio >3.0; younger age at onset; higher rates of Class IV lupus nephritis; higher rates of end-organ damage at diagnosis; lower overall survival compared to white women with equivalent disease[4]
  • Biological factors: Specific antibody patterns more common in Black women — including anti-Sm and antiphospholipid antibodies — associated with more severe disease[38]
  • Healthcare access and structural inequity: Delayed diagnosis (longer time from symptom onset to rheumatology referral); reduced access to nephrology and rheumatology specialty care; lower rates of hydroxychloroquine use (the single medication with the strongest survival benefit in SLE); socioeconomic barriers to medication adherence[39]
  • Asian and Hispanic women: Also disproportionately affected with higher incidence and severity compared to white women[2]
  • Clinical acknowledgment: The Black woman dying from lupus nephritis at 42 has experienced not only the disease but the specific inequity that shaped how that disease was managed; the hospice clinician must acknowledge these disparities directly[40]

❤️ For Families: "Why Did This Happen?"

Rheumatoid arthritis and lupus are autoimmune diseases — the body's immune system, which normally fights infections, mistakenly attacks the body's own tissues. Your loved one did not cause this disease. Nobody chooses to develop an autoimmune condition. RA and SLE are caused by a combination of genetic susceptibility (certain genes that run in families) and environmental triggers (such as infections or hormonal factors) that activate the immune system against the body's own joints, kidneys, heart, and other organs.[28] In SLE, this immune misdirection can affect almost any organ in the body, which is why the disease is so unpredictable and so exhausting to manage over decades. Your loved one has been fighting this disease for years — through medication changes, side effects, flares, and complications — with a courage that deserves recognition. The disease and its treatments have shaped their body in visible ways (the effects of long-term steroids, the changes in their joints) that they have lived with for a long time. When they arrive at hospice, they bring not just a medical history but a lifetime of managing a disease that never let them rest.[5]

⚕ Clinician Note: Atlanto-Axial Subluxation Screening at Enrollment

Every RA patient admitted to hospice must have their cervical spine status assessed before any positioning care is provided. Atlanto-axial instability (AAI) occurs in up to 25–40% of patients with long-standing RA and may be clinically silent until a catastrophic event.[23] Review existing cervical spine imaging (lateral flexion-extension radiographs or MRI). If C1-C2 distance exceeds 3 mm, the AAI restriction must be documented as the first safety alert in the care plan and communicated to every caregiver — including aides, family members, and physical therapists — before any repositioning, transfers, or personal care is delivered. The restriction is absolute: no neck hyperflexion under any circumstance. Neutral or slight extension must be maintained at all times. The cervical collar must be positioned at the bedside and worn during all movement activities.[41] This is not a theoretical risk — it is the most dangerous unrecognized positioning hazard in rheumatological hospice, and it must be treated with the same urgency as a morphine contraindication in ESRD.

S04ClinicianEveryone

Treatments & Procedures

End-stage RA and SLE symptom management — corticosteroid protocols, joint contracture positioning, multi-mechanism pain management, immunosuppression decisions, and PCP prophylaxis.

RA and SLE end-stage symptom management requires a comprehensive clinical framework built on three non-negotiable safety priorities established at enrollment before any other clinical assessment. First: the corticosteroid physiological replacement dose cannot be stopped — calculate the minimum (prednisone 5–7.5 mg/day equivalent) and establish the taper plan. Second: the atlanto-axial subluxation cervical collar protocol must be communicated if documented. Third: PCP prophylaxis status must be assessed and started at enrollment if absent.[6][23][25] Beyond these three safety acts, the treatment framework addresses the full spectrum of RA/SLE end-stage complications through disease-specific and symptom-specific management pathways.

The corticosteroid management at hospice enrollment is the most dangerous medication to mismanage in RA/SLE hospice. The corticosteroid-dependent patient who has been on prednisone for years cannot have their corticosteroids abruptly stopped. The HPA axis suppression from chronic corticosteroid use produces adrenal insufficiency that will manifest as hypotension, fatigue, nausea, vomiting, and potentially addisonian crisis when corticosteroids are suddenly withdrawn.[42] Any patient on prednisone 5–7.5 mg/day or more for more than 3 months has significant HPA axis suppression. The physiological cortisol replacement dose is equivalent to prednisone 5–7.5 mg/day. The minimum dose at hospice is the lowest dose that prevents adrenal insufficiency and maintains enough anti-inflammatory effect to manage symptoms. The taper from the current dose to the physiological replacement dose should be gradual — reduce by 1–2 mg per week.[43] At end stage, the question is not whether to continue some corticosteroid (yes — always the minimum physiological replacement dose) but whether the higher immunosuppressive doses are serving comfort goals. A patient in comfort-directed care may not need 20 mg/day of prednisone but will need 5–7.5 mg/day for adrenal replacement. Document the taper plan. Write "NEVER STOP PREDNISONE — ADRENAL INSUFFICIENCY RISK — MINIMUM DOSE [X] MG/DAY" in the medication safety section.[6]

Corticosteroid Taper Protocol
Grade A
Prednisone → minimum 5–7.5 mg/day PO (physiological replacement)
  • Current dose >20 mg/day: Reduce by 5 mg every 1–2 weeks until reaching 20 mg/day[43]
  • Current dose 10–20 mg/day: Reduce by 2.5 mg every 1–2 weeks until reaching 10 mg/day
  • Current dose 5–10 mg/day: Reduce by 1 mg every 2–4 weeks to the minimum physiological dose (5–7.5 mg/day)
  • Below 5 mg/day: Do not reduce further in patients with documented chronic use >3 months — adrenal insufficiency risk is high[42]
  • If patient is vomiting and cannot take oral prednisone: Administer IV/IM hydrocortisone 50–100 mg as stress-dose replacement; have emergency injectable corticosteroid in the home[6]
  • ⚠ NEVER STOP ABRUPTLY: Adrenal crisis from abrupt cessation produces hemodynamic collapse; this is as dangerous as morphine in ESRD — document with equal prominence
Joint Contracture Positioning Protocol — End-Stage RA
Grade B

The end-stage RA patient with fixed joint contractures requires positioning management specifically adapted to the contracture pattern:[36]

  • Hand contractures: Cotton gauze padding placed in the web spaces prevents moisture damage and maceration from skin-on-skin contact; miconazole powder for any candidal colonization; do NOT force extension — the contracted hand that has been in fixed flexion for years cannot be straightened without pain and potential fracture[35]
  • Elbow contractures: Position with the elbow at the patient's established flexion angle; use foam padding at pressure points; the contracted elbow is at high risk for olecranon pressure injury
  • Hip and knee contractures: Positioning wedges under flexed knees; lateral positioning with pillows between contracted knees; the standard supine position is impossible in patients with bilateral hip and knee flexion contractures — do not force flat[22]
  • Atlanto-axial subluxation protocol: Cervical collar for all repositioning and transfers; head of bed elevation without neck flexion; pillow under the occiput so the neck is in slight extension, not flexion; two-person assist with one person dedicated to maintaining neutral neck position[23]
Multi-Mechanism Pain Management
Grade A

The chronic pain of severe RA and SLE is mechanistically complex — all pain mechanisms must be addressed simultaneously:[44]

  • Inflammatory pain (active synovitis, serositis): NSAIDs (if renal function allows — eGFR >30); corticosteroids at the minimum effective dose above the physiological replacement; for serositis-specific pain: indomethacin 25–50 mg TID or colchicine 0.6 mg BID for pericarditis[45]
  • Neuropathic pain (vasculitic neuropathy, medication toxicity): Gabapentin 100–300 mg TID (start low, titrate slowly — renal dosing if eGFR impaired); pregabalin 25–75 mg BID as alternative; tricyclic antidepressants (nortriptyline 10–25 mg QHS) if tolerated[46]
  • Structural nociceptive pain (joint destruction, AVN, fractures): Scheduled acetaminophen 500–1000 mg q6h as baseline; opioids for moderate-to-severe structural pain — morphine IR 5–15 mg q4h PRN (renally dose if eGFR <30; substitute hydromorphone if ESRD); fentanyl transdermal for stable chronic structural pain[47]
  • Visceral pain (serositis — pericarditis, pleuritis): NSAIDs are first-line if renal function permits; corticosteroids for NSAID-refractory or renal-impaired serositis pain; colchicine for recurrent pericarditis[11]
  • Muscle spasm pain (secondary to contractures): Baclofen 5–10 mg TID; cyclobenzaprine 5–10 mg QHS; topical diclofenac for localized joint pain with preserved skin integrity
Immunosuppression Management at End Stage
Grade B

Each immunosuppressive agent requires individual comfort-benefit reassessment at hospice enrollment:[7]

  • Methotrexate: Reassess benefit — if disease activity is not the primary symptom driver at end stage, the hepatotoxicity, myelosuppression, and infection risk may outweigh the anti-inflammatory benefit; if continuing, ensure folic acid supplementation and monitor CBC[48]
  • Hydroxychloroquine: Generally the safest DMARD to continue; retinal toxicity is a long-term concern but not relevant at end stage; maintains a mild anti-inflammatory and anti-thrombotic benefit; most SLE experts recommend continuation[49]
  • Mycophenolate mofetil: If controlling active lupus nephritis, the comfort-benefit depends on whether ESRD is being prevented or delayed vs. the infection risk being added; if ESRD is already established, mycophenolate may not serve comfort goals
  • TNF inhibitors / rituximab / belimumab: Reassess infusion burden, infection risk, and cost against the specific comfort benefit; the biologic that reduced joint inflammation five years ago may be adding only infection risk and IV burden at end stage[8]
  • Cyclophosphamide: Rarely appropriate at end stage; the myelosuppression, hemorrhagic cystitis risk, and infection risk typically outweigh comfort benefit; exception: actively life-threatening cerebral vasculitis in NPSLE where the patient and family choose aggressive treatment
PCP Prophylaxis and Infection Management
Grade A

PCP prophylaxis is a comfort medication in the immunosuppressed hospice patient because PCP produces the most distressing dyspnea burden of any opportunistic infection:[25]

  • Indications for prophylaxis: Prednisone >20 mg/day for >1 month; combination of 2+ immunosuppressants; prior PCP episode; CD4 count <200 (if checked)
  • First-line: Trimethoprim-sulfamethoxazole (TMP-SMX) single-strength daily — most effective prophylaxis agent[50]
  • TMP-SMX intolerance: Dapsone 100 mg daily (check G6PD before starting in appropriate populations — African American, Mediterranean, Asian patients); atovaquone 1500 mg daily as third-line[51]
  • If PCP develops despite prophylaxis: TMP-SMX at treatment doses (15–20 mg/kg/day of TMP component) for 21 days; adjunctive prednisone 40 mg BID × 5 days, then 40 mg daily × 5 days, then 20 mg daily × 11 days if PaO2 <70 mmHg; this treatment is consistent with comfort goals because untreated PCP produces progressive respiratory failure with severe dyspnea
  • Other infections to anticipate: Herpes zoster reactivation (acyclovir/valacyclovir); oral/esophageal candidiasis (fluconazole); bacterial pneumonia (empiric antibiotics appropriate for comfort); CMV reactivation in heavily immunosuppressed patients[8]
SLE-Specific End-Stage Treatments
Grade B

SLE produces organ-specific complications requiring targeted management at end stage:[9]

  • Lupus nephritis → ESRD: Apply the Card #47 framework for dialysis decision-making; the lupus anticoagulant in APS-positive patients complicates heparin use during hemodialysis; document the dialysis withdrawal conversation early[26]
  • NPSLE seizure management: Continue anticonvulsants (levetiracetam 500–1500 mg BID preferred; valproate or phenytoin as alternatives); do not discontinue — seizure recurrence produces significant patient and family distress; advance directive should address seizure management preference[10]
  • NPSLE cognitive impairment: Apply the same communication accommodations as Cards #52 and #60; short, clear instructions; familiar routines; assess decision-making capacity early
  • APS anticoagulation: Warfarin with target INR 2.0–3.0 for venous thrombosis, 3.0–4.0 for recurrent events or arterial thrombosis; DOACs are inferior to warfarin in triple-positive APS (TRAPS trial); reassess comfort-benefit against bleeding risk at enrollment[52]
  • Serositis management: Pericarditis — NSAIDs (indomethacin 25–50 mg TID) + colchicine 0.6 mg BID if renal function allows; corticosteroid dose increase for NSAID-refractory or renal-impaired serositis; pleuritis — same analgesic approach[11]
  • Accelerated atherosclerosis / heart failure: Standard heart failure management (Card #44 framework); statin continuation is reasonable if tolerated; aspirin for secondary cardiovascular prevention if not contraindicated by bleeding risk[12]
Non-Pharmacological Comfort Measures
Expert Consensus
  • Paraffin wax baths for hand pain: Warm paraffin applied to contracted hands provides temporary analgesia and improved range of motion; the warmth reduces nociceptive signaling from the structural joint destruction; perform 1–2× daily as tolerated[53]
  • Moist heat therapy: Warm compresses or heated blankets applied to painful joints; 15–20 minutes, 2–3× daily; avoid over contracted skin with impaired sensation
  • Splinting: Resting splints for wrists and hands to maintain position of comfort (not correction); night splints to prevent further contracture progression if tolerated; do not force joints beyond their current range
  • Gentle range-of-motion exercises: Passive ROM within the pain-free range only; performed by a physical therapist or trained caregiver who understands RA contracture limits; never force past the established contracture point[36]
  • Pressure injury prevention: Alternating pressure mattress; repositioning every 2 hours; special attention to olecranon, greater trochanter, and sacral pressure in patients with limited positioning options due to contractures[35]
  • Skin care for steroid-damaged skin: Gentle emollients for thin, fragile skin; minimal adhesive use (skin tears easily in chronic steroid patients); careful venipuncture technique if needed
DMARD and Biologic Comfort-Benefit Decision Framework
Expert Consensus

Each agent in the RA/SLE medication regimen must be assessed against a single question: Is this medication providing more comfort than burden in the remaining time?[54]

  • Continue if: The agent is directly controlling a symptom that impairs comfort (e.g., hydroxychloroquine preventing SLE flares; low-dose prednisone for inflammatory pain; anticonvulsant for NPSLE seizures; warfarin preventing recurrent APS thrombosis)
  • Reassess if: The agent was prescribed for long-term disease modification but the patient's prognosis is weeks to months (e.g., methotrexate for RA progression; mycophenolate for nephritis in established ESRD; biologic infusions requiring clinic visits)[7]
  • Discontinue if: The agent adds burden without identifiable comfort benefit (e.g., IV rituximab infusions in a patient with weeks of prognosis; cyclophosphamide when infection risk exceeds disease-control benefit; bisphosphonates for osteoporosis prevention when prognosis is <6 months)
  • Never discontinue: Prednisone below the physiological replacement dose (5–7.5 mg/day); anticonvulsants for active seizure disorder; PCP prophylaxis in the immunosuppressed patient; the medication that prevents a symptom worse than the medication's burden[6]
S05Clinician

When Therapy Makes Sense

The specific clinical acts, safety protocols, and therapeutic interventions that serve comfort in severe RA and SLE at end of life.

In severe RA and SLE, "therapy that makes sense" at hospice enrollment is not disease remission — it is the set of clinical safety acts and symptom management protocols that must be established before any care is delivered. Unlike oncological hospice where the therapy-versus-comfort decision centers on chemotherapy continuation, RA/SLE hospice requires a different framework: the patient's decades-long medication regimen includes agents that are simultaneously therapeutic and life-sustaining (corticosteroids for adrenal replacement), agents that are prophylactic against catastrophic infections (TMP-SMX for PCP prevention), and positioning protocols that prevent iatrogenic spinal cord injury (atlanto-axial subluxation restriction). The "therapy that makes sense" in this population is the clinical safety infrastructure that must be in place at enrollment — not optional, not deferrable, and not subject to the medication simplification logic that applies to other hospice diagnoses.[1][12]

  1. 01
    Atlanto-axial subluxation (AAI) communication at enrollment — the first clinical safety act in RA hospice. Before any caregiver touches the patient, review the cervical spine imaging. If AAI is documented (C1-C2 anterior atlanto-dental interval >3 mm on lateral radiograph or MRI), the cervical collar protocol must be communicated to every aide, every family member, and every covering clinician before any repositioning, transfer, or personal care is performed. Post the restriction in the patient's room. Document it as the first line in the care plan safety alerts. The cervical collar (Philadelphia or soft collar) must be worn during all repositioning and transfers. Neutral neck position at all times — no pillow stacking that forces chin-to-chest flexion. The aide who provides morning care without knowing about AAI has been set up by a clinical system that failed to communicate the most dangerous positioning restriction in rheumatological hospice.[13][14]
  2. 02
    Corticosteroid minimum physiological replacement dose established at enrollment — the medication that cannot be stopped. The patient who has been on prednisone for years has iatrogenic HPA axis suppression. Calculate the minimum physiological replacement dose: prednisone 5–7.5 mg/day equivalent. Taper from the current dose (which may be 15–40 mg/day for active disease management) to this minimum over weeks — reduce by 1–2 mg per week. The minimum dose must be continued throughout the end-of-life course regardless of other medication simplifications. Document the taper plan and the adrenal insufficiency risk at the top of the medication list with the same prominence as morphine contraindication in ESRD. Abrupt cessation produces addisonian crisis: hypotension, nausea, vomiting, cardiovascular collapse.[17][18]
  3. 03
    PCP prophylaxis at enrollment for any patient on significant immunosuppression. Pneumocystis jirovecii pneumonia in non-HIV immunosuppressed patients produces a severe dyspnea syndrome that is among the most distressing infection presentations in hospice. TMP-SMX single-strength one tablet daily is the standard prophylaxis; alternatives for sulfa-intolerant patients: dapsone 100 mg daily (with G6PD check in Black patients and other at-risk populations) or atovaquone 1500 mg daily. Prophylaxis is indicated for any patient on prednisone >20 mg/day for >4 weeks, on two or more immunosuppressants, or with a prior PCP episode. The PCP prophylaxis is a comfort medication — it prevents a predictable, preventable, profoundly distressing respiratory infection. Start it at enrollment if not already prescribed.[21][22]
  4. 04
    Multi-modal pain management addressing all five RA/SLE pain mechanisms simultaneously. The chronic pain of end-stage RA/SLE is mechanistically heterogeneous and requires simultaneous targeting: (1) opioids for structural nociceptive pain from joint destruction, avascular necrosis, and compression fractures; (2) gabapentinoids (gabapentin 300–1200 mg TID or pregabalin 75–150 mg BID) for neuropathic pain from vasculitic neuropathy or methotrexate neurotoxicity; (3) NSAIDs for inflammatory and serositis pain if eGFR >30 — if renal function is compromised, use corticosteroids instead; (4) low-dose corticosteroids at physiological replacement providing background anti-inflammatory analgesia; (5) positioning modification and topical agents (lidocaine 5% patch, diclofenac gel if renal function allows) for focal mechanical contracture pain. Document each analgesic component with its specific mechanism target.[37][38]
  5. 05
    Joint contracture-specific positioning protocol at enrollment. The end-stage RA patient with fixed joint contractures requires positioning management specifically adapted to the contracture pattern: web space padding with cotton gauze in the web spaces of contracted hands to prevent maceration, fungal infection, and pressure injury from skin-on-skin contact; cervical collar for AAI; positioning wedges for hip and knee flexion contractures that cannot be straightened — accommodate the contracture angle rather than fighting it; specialist wound care referral for any pressure injury in a contractured joint. This is the pressure injury prevention protocol that standard wound care protocols miss because they focus on bony prominences rather than contracture-specific locations.[29][30]
  6. 06
    Lupus nephritis ESRD framework from Card #47 if dialysis is part of the clinical picture. Lupus nephritis (Class III–IV) that progresses to ESRD requiring dialysis triggers the full Card #47 dialysis withdrawal framework: the 7–14 day post-withdrawal survival timeline; fentanyl (not morphine) for pain management (morphine-6-glucuronide accumulation in ESRD causes neurotoxic encephalopathy); uremic pruritus management with gabapentin and mirtazapine; hyperkalemia dietary restriction; and the specific SLE-APS interaction — the patient with SLE-ESRD on dialysis who also has antiphospholipid syndrome has dialysis access thrombosis risk that significantly complicates vascular access management.[23][24]
  7. 07
    NPSLE seizure management — anticonvulsant continuation with advance directive addressing seizure management preference. The patient with neuropsychiatric SLE who has established seizures must have their anticonvulsant regimen continued without interruption. Levetiracetam is preferred in SLE because it has minimal drug interactions with the immunosuppressive regimen and no hepatic CYP induction that would alter methotrexate or calcineurin inhibitor levels. The advance directive must specifically address seizure management preference: does the patient want benzodiazepine rescue (lorazepam 2–4 mg IV/IM) for prolonged seizures? Is status epilepticus to be treated aggressively or with comfort-focused measures? Document the seizure plan prominently.[33][34]
  8. 08
    APS anticoagulation reassessment at hospice enrollment. The patient with antiphospholipid syndrome on warfarin (target INR 2–3 for venous thrombosis, 3–4 for arterial events) requires explicit comfort-benefit reassessment of anticoagulation against the accumulated bleeding risk — thrombocytopenic lupus, RA joint bleeding, renal failure-associated platelet dysfunction. If anticoagulation continues, document the rationale and the INR monitoring plan. If anticoagulation is discontinued, document the thrombosis risk and the patient-family discussion. Note: DOACs are not recommended for APS anticoagulation per the TRAPS trial — warfarin remains the standard.[25][26]
  9. 09
    Rheumatologist co-management through hospice enrollment. The rheumatologist who has managed the patient for 15–30 years has disease-specific knowledge that the hospice team needs — the baseline joint contracture map, the flare pattern, the medication sensitivities, the cervical spine imaging history. Contact the rheumatologist at enrollment. Establish a communication protocol for clinical questions that arise. The rheumatologist's involvement does not conflict with hospice goals — it provides continuity with the clinical team that knows this specific disease in this specific patient better than any new provider can learn in weeks.[1][47]
  10. 10
    Steroid-thinned skin care and steroid-induced osteoporosis management at hospice enrollment. Decades of corticosteroids produce skin fragility (thin, easily torn, poor wound healing) requiring emollient application twice daily and wound care for any skin tears as in Card #56. Calcium (1000–1200 mg/day divided) and vitamin D (2000–4000 IU daily) continuation for steroid-induced osteoporosis is appropriate for comfort — muscle and bone pain from severe vitamin D deficiency is a treatable source of suffering. Bisphosphonate continuation should be reassessed per STOPPFrail criteria (Card #52): if prognosis is months, the fracture prevention rationale no longer justifies the pill burden, esophageal irritation risk, and osteonecrosis of the jaw concern.[39][40]
S06Clinician

When It Doesn't

The specific clinical thresholds where interventions cause more harm than benefit in end-stage RA and SLE.

The medication errors and care delivery failures that cause the most harm in RA/SLE hospice are not exotic clinical misjudgments — they are routine simplification decisions applied to a disease that does not tolerate routine simplification. The hospice team accustomed to deprescribing statins, bisphosphonates, and antihypertensives in geriatric frailty hospice (Card #52) must recognize that RA/SLE carries non-negotiable medication dependencies and positioning restrictions that cannot be simplified away. Every item below represents a documented or predictable harm pathway specific to this population.[17][47]

  1. 01
    Abrupt corticosteroid cessation in a patient with chronic steroid use — adrenal crisis will occur. This is among the most dangerous medication errors in RA/SLE hospice. The minimum physiological replacement dose (prednisone 5–7.5 mg/day equivalent) must be continued throughout the entire end-of-life course regardless of all other medication simplifications. Do not reduce below 5 mg/day in any patient with documented chronic steroid use of more than 3 months. The covering nurse who stops the prednisone at 2 AM while "simplifying medications" will produce addisonian crisis — hypotension, nausea, vomiting, cardiovascular collapse — within 24–48 hours. Document the adrenal insufficiency risk as prominently in the care plan as the morphine contraindication in ESRD (Card #47).[17][18]
  2. 02
    NSAIDs in any patient with lupus nephritis and eGFR below 30 — absolute contraindication. The same absolute contraindication as in SSc renal crisis (Card #59) and ESLD (Card #49). NSAIDs inhibit prostaglandin-mediated afferent arteriolar vasodilation, reducing renal blood flow and accelerating CKD progression. The serositis pain (pleuritis, pericarditis) that is most effectively treated with NSAIDs must be treated with corticosteroids instead when renal function is compromised. Document the renal function and the NSAID contraindication explicitly in the care plan. This includes all forms — oral, topical, and any herbal supplements with NSAID-like activity (willow bark, high-dose Boswellia).[23][37]
  3. 03
    Forcing extension of fixed joint contractures — accommodate, do not fight. The contracted hand that has been in fixed flexion for years cannot be forced into extension without causing pain, soft tissue injury, and potential fracture through osteoporotic bone. The positioning protocol must accommodate the contracture, not reverse it. The aide who attempts to straighten the contracted fingers for hygiene without specific training on RA contracture management has caused harm — potentially fracturing phalanges through steroid-osteoporotic bone. Communicate the contracture management protocol to every caregiver with the same specificity as the AAI restriction. Lift the fingers gently for web space inspection; do not force them apart.[29][30]
  4. 04
    Escalating immunosuppressive DMARDs and biologics without reassessing the comfort-benefit ratio. The biologic DMARD (adalimumab, etanercept, rituximab, tocilizumab) that reduced joint inflammation meaningfully five years ago may be adding significant infection risk, IV infusion burden, subcutaneous injection discomfort, monitoring requirements, and high cost without providing measurable comfort benefit at end stage. Reassess each immunosuppressive agent against the single question: "Is this medication reducing suffering today?" The DMARD that is continued out of inertia rather than active clinical benefit assessment may be the medication producing the recurrent infections that are driving the patient's decline. Discuss deprescribing with the rheumatologist.[41][42]
  5. 05
    Methotrexate continuation in significant hepatic involvement. The liver that is failing from methotrexate-induced fibrosis (cumulative dose-related hepatotoxicity after years of weekly dosing) combined with corticosteroid-driven hepatic steatosis cannot tolerate continued methotrexate. If ALT/AST is persistently elevated above 2× upper limit of normal, if hepatic fibrosis is documented on imaging or biopsy, or if the patient has concurrent viral hepatitis, methotrexate must be reassessed with the rheumatologist. Methotrexate also requires adequate renal function for clearance — in lupus nephritis CKD with eGFR below 30, methotrexate accumulation produces severe pancytopenia and mucositis. Check both hepatic and renal function before continuing.[43][44]
  6. 06
    Anticoagulation continuation without reassessment in a patient with high bleeding risk. The warfarin anticoagulation for APS that was appropriate at diagnosis may need reassessment against the bleeding risk that has accumulated: thrombocytopenic lupus (platelet count <50,000 creates dual risk — thrombosis from APS and hemorrhage from thrombocytopenia), RA joint bleeding into contracted joints, and renal failure-associated platelet dysfunction in lupus nephritis ESRD. The anticoagulation decision must be documented with explicit risk-benefit analysis at enrollment. A patient with APS and platelet count below 50,000 requires hematology consultation for the anticoagulation-thrombocytopenia overlap.[25][26]
  7. 07
    Trendelenburg positioning in a patient with atlanto-axial subluxation — absolutely contraindicated without specific neck stabilization. Trendelenburg positioning (head lower than feet) causes the head to flex forward under gravity. In a patient with documented C1-C2 subluxation, this neck flexion can compress the spinal cord at the cervicomedullary junction, producing acute tetraplegia or death. This is not a theoretical risk — it is a documented mechanism of catastrophic injury in RA cervical spine disease. If Trendelenburg is clinically indicated for any reason, specific cervical stabilization with a rigid collar must be applied first, and the positioning must be supervised. In most hospice scenarios, Trendelenburg should simply be avoided entirely.[13][15]
  8. 08
    High-dose dexamethasone for NPSLE psychosis without differentiating from steroid-induced psychosis. Corticosteroid-induced psychosis occurs in up to 5–6% of patients on high-dose corticosteroids (prednisone equivalent >40 mg/day). The clinical presentation — agitation, hallucinations, paranoia, disorganized thought — can mimic NPSLE psychosis. If the patient develops psychosis while on high-dose steroids, increasing the steroid dose (the treatment for NPSLE psychosis) when the cause is actually steroid psychosis will catastrophically worsen the condition. The clinical differentiation requires careful timeline assessment: steroid psychosis typically emerges 3–11 days after dose escalation and resolves with dose reduction; NPSLE psychosis correlates with other lupus activity markers (rising anti-dsDNA, falling complement). When the presentation is ambiguous, request neuropsychiatry consultation before escalating corticosteroids.[33][35]

⚠️ The Non-Negotiable Three in RA/SLE Hospice

Three medication and positioning decisions in RA/SLE hospice are non-negotiable and non-deferrable — they must be documented at enrollment and communicated to every covering clinician, every aide, and every family member:

  • Prednisone physiological replacement dose cannot be stopped. Minimum 5 mg/day in any patient on chronic steroids >3 months. Document as safety alert.
  • Atlanto-axial subluxation cervical collar protocol must be communicated before any care is delivered. No neck hyperflexion under any circumstance. Post the restriction in the room.
  • PCP prophylaxis must be assessed and started at enrollment if the patient is on significant immunosuppression without existing prophylaxis. This is a preventable comfort failure.

The hospice team that fails to establish these three safety acts at enrollment has created a care environment where the most predictable harms in RA/SLE hospice can occur. These are not edge cases — they are the standard clinical obligations for this population.[14][18][22]

S07Everyone

Out-of-the-Box Approaches

Evidence-graded integrative, interventional, and complementary approaches. Grade A = RCT; B = multi-observational/meta-analysis; C = limited clinical, strong preclinical; D = expert opinion.

Atlanto-Axial Subluxation (AAI) Care Protocol
Grade A
Protocol: Cervical collar (Philadelphia or soft) for ALL repositioning, transfers, personal care; neutral neck position at all times; post restriction in patient's room
The most urgent and most specific safety act in RA hospice. Atlanto-axial subluxation from RA pannus erosion of the transverse ligament at C1-C2 is present in 25–50% of patients with long-standing erosive RA. The C1-C2 anterior atlanto-dental interval >3 mm on lateral cervical radiograph or MRI documents instability. Forced neck flexion in AAI can produce acute spinal cord compression at the cervicomedullary junction — causing tetraplegia or death. The AAI care protocol is adapted from perioperative anesthesia guidelines for RA cervical spine disease, applied to the daily care setting:
  • Cervical collar worn during all repositioning, transfers, bed adjustments, and personal care
  • Pillow positioned under the occiput to maintain slight neck extension — never chin-to-chest flexion
  • Two-person assist for all transfers with one person dedicated to maintaining neutral neck position
  • Head of bed elevation achieved without neck flexion
  • Family trained on AAI restriction with same urgency as no-morphine rule in ESRD
  • Restriction posted in patient's room before any caregiver enters
Document the AAI protocol as the first clinical safety alert in the care plan.[13][14][15]
Physiological Corticosteroid Replacement Dose
Grade A
Dose: Prednisone 5–7.5 mg/day equivalent — the minimum physiological replacement. Taper from current dose at 1–2 mg/week. Never stop below 5 mg/day.
The steroid that cannot be stopped — adrenal insufficiency prevention in chronic steroid-dependent RA/SLE. Hypothalamic-pituitary-adrenal (HPA) axis suppression from chronic corticosteroid use (>3 months) is irreversible in most patients who have been on steroids for decades. The suppressed HPA axis cannot mount a cortisol response to physiological stress, infection, surgery, or corticosteroid withdrawal. The consequences of adrenal insufficiency: hypotension, nausea, vomiting, abdominal pain, fatigue, confusion, and addisonian crisis with cardiovascular collapse.
  • Calculate minimum physiological dose at enrollment — prednisone 5–7.5 mg/day equivalent
  • Taper from current dose to minimum over weeks (1–2 mg/week reduction)
  • Document "NEVER STOP PREDNISONE — ADRENAL INSUFFICIENCY RISK" prominently in safety alerts
  • Ensure injectable hydrocortisone (100 mg IM) is available for emergency adrenal crisis
  • Administer with food; continue gastroprotective PPI
The medication simplification appropriate for geriatric frailty hospice (Card #52) applies here with this specific, absolute exception.[17][18][19]
PCP Prophylaxis in Immunosuppressed RA/SLE
Grade A
Dose: TMP-SMX SS 1 tab daily (or 3×/week for lower risk); Alternatives: dapsone 100 mg daily (check G6PD) or atovaquone 1500 mg daily
The antibiotic that prevents the most distressing opportunistic infection in immunosuppressed hospice. Pneumocystis jirovecii pneumonia (PCP) in non-HIV immunosuppressed patients produces profound hypoxemia, severe air hunger, and refractory dyspnea that constitutes one of the most distressing infection presentations in all of hospice care. The PCP mortality rate in non-HIV immunosuppressed patients is 30–60% — substantially higher than in HIV-associated PCP. EULAR, ACR, and IDSA recommend TMP-SMX prophylaxis for:
  • Prednisone >20 mg/day for >4 weeks
  • Two or more concurrent immunosuppressants
  • Prior PCP episode — lifelong secondary prophylaxis
  • Lymphopenia <600 cells/μL from immunosuppression
For sulfa-intolerant patients: dapsone 100 mg daily requires G6PD screening (prevalence 10–14% in Black males); atovaquone 1500 mg daily is the alternative. The PCP that develops in an unprotected immunosuppressed hospice patient is a preventable clinical failure — start prophylaxis at enrollment if not already prescribed.[21][22][20]
Web Space Padding for RA Hand Contractures
Grade A
Protocol: Cotton gauze padding in web spaces at every personal care visit; miconazole powder for erythema/maceration; daily assessment and replacement
The pressure injury prevention intervention that standard protocols miss. The fixed-flexion hand contractures of end-stage RA produce continuous skin-on-skin contact in the finger web spaces — the same moist, occluded environment that causes intertrigo in obesity (Card #51). Without intervention, web spaces develop maceration, fungal infection (Candida), and pressure injury from prolonged contact.
  • Place cotton gauze gently within the existing web space — do not force fingers apart
  • Gauze absorbs moisture and prevents skin-on-skin maceration
  • Change daily or when soiled; assess web spaces at every nursing visit
  • Apply miconazole 2% powder to any area showing erythema or white maceration
  • Train family to check web spaces during personal care
  • Document web space status as a clinical assessment at every visit
Standard wound care protocols focus on bony prominences (sacrum, heels, trochanters); RA contracture-specific locations require explicit addition to the pressure injury prevention plan.[29][30][31]
Lupus Nephritis ESRD — Card #47 Dialysis Framework
Grade A
Framework: Apply full Card #47 dialysis withdrawal protocol with SLE-APS specific modifications; fentanyl not morphine; 7–14 day post-withdrawal timeline
Applying the dialysis withdrawal framework at the intersection of SLE and renal failure. Lupus nephritis (Class III–IV proliferative glomerulonephritis) is the most common cause of death in SLE and the most common cause of ESRD from autoimmune disease. The SLE-ESRD patient requiring the Card #47 framework needs specific modifications:
  • Opioid safety: Fentanyl, not morphine — morphine-6-glucuronide accumulation in ESRD produces neurotoxic encephalopathy; hydromorphone is an acceptable alternative
  • APS-dialysis interaction: The SLE patient with concurrent APS has dialysis access thrombosis risk from antiphospholipid antibodies; anticoagulation for access patency conflicts with uremic coagulopathy bleeding risk
  • Post-withdrawal timeline: 7–14 days median survival after dialysis withdrawal; uremic symptoms (drowsiness, nausea, myoclonus) managed with symptom protocol
  • Uremic pruritus: Gabapentin 100–300 mg post-dialysis (dose-adjust for ESRD) plus mirtazapine 7.5–15 mg at bedtime
  • Written timeline for family: Provide the family with the post-withdrawal symptom timeline so they know what to expect day by day
Document the SLE-ESRD overlap explicitly and the specific modifications to the standard Card #47 protocol.[23][24][27]
Multidimensional Chronic Pain — STT Matrix Protocol
Grade B
Protocol: Simultaneous targeting of all 5 pain mechanisms — opioids + gabapentinoids + anti-inflammatory + topical + positioning; document each component with its target mechanism
Simultaneous targeting of all five RA/SLE pain mechanisms. The chronic pain of end-stage RA and SLE is mechanistically heterogeneous — the single-agent opioid strategy that treats only nociceptive pain while leaving inflammatory, neuropathic, serositis, and contracture-mechanical components unaddressed provides inadequate pain management. The specific multi-modal protocol:
  • Structural nociceptive: Opioids (long-acting oxycodone or fentanyl patch) for joint destruction, avascular necrosis, compression fracture pain
  • Inflammatory/serositis: NSAIDs (if eGFR >30) or corticosteroids for pleuritis, pericarditis, active synovitis
  • Neuropathic: Gabapentin 300–1200 mg TID or pregabalin 75–150 mg BID for vasculitic neuropathy, methotrexate neurotoxicity
  • Topical/focal: Lidocaine 5% patch for localized joint pain; diclofenac gel (if renal function allows); capsaicin 0.025–0.1% for accessible joints
  • Mechanical/contracture: Positioning wedges, heated blankets, paraffin wax baths for contracted hands (as in SSc Card #59) for morning stiffness
The analgesic synergy from multi-modal targeting often allows the opioid dose to be lower than if opioids were used alone — reducing opioid side effects while improving overall pain control. Document each component with its mechanism target.[37][38][36]
NPSLE Seizure & Cognitive Impairment Management
Grade B
Protocol: Continue established anticonvulsant (levetiracetam preferred); seizure rescue: lorazepam 2–4 mg IV/IM PRN; document seizure advance directive
Neuropsychiatric SLE management at end of life — seizures, cognitive decline, and the steroid-versus-NPSLE differentiation. Neuropsychiatric SLE (NPSLE) occurs in 30–40% of SLE patients and includes seizures (10–20% of SLE patients), cognitive impairment ("lupus fog"), psychosis, and cerebrovascular disease. At end of life, the clinical priorities are:
  • Anticonvulsant continuation: Levetiracetam preferred — minimal drug interactions with immunosuppressive regimen, no hepatic CYP induction; valproate avoided if hepatic impairment; phenytoin avoided due to CYP induction reducing immunosuppressant levels
  • Seizure advance directive: Explicitly address whether the patient wants aggressive seizure management (intubation for status epilepticus) or comfort-focused seizure management (benzodiazepine rescue only)
  • Cognitive impairment: "Lupus fog" is a recognized NPSLE manifestation — memory impairment, executive dysfunction, reduced processing speed; distinguish from medication side effects (methotrexate neurotoxicity, opioid cognitive effects) and from delirium
  • Steroid psychosis differentiation: If psychosis emerges during high-dose steroid use, the steroid dose should be reduced, not increased; NPSLE psychosis requires steroid escalation — the wrong direction kills the patient
The ACR NPSLE case definitions provide the nomenclature for documenting specific NPSLE manifestations.[33][34][35]
Heat Therapy & Paraffin Wax Baths for Contracture Pain
Grade B
Protocol: Paraffin wax baths for contracted hands at 52–54°C for 15–20 min; heated blankets for morning stiffness; warm compresses for knee/hip contracture pain
Non-pharmacological analgesia for the mechanical pain of joint contractures and morning stiffness. Heat therapy for RA joint pain has Level B evidence from multiple controlled trials demonstrating reduction in morning stiffness duration, joint tenderness, and pain scores. Paraffin wax baths are specifically effective for contracted hands — the wax conforms to the deformed joint surfaces and provides sustained, even heat transfer that heated towels cannot match.
  • Paraffin baths for hands: Temperature 52–54°C; dip-and-wrap method for 15–20 minutes; the wax provides heat therapy and skin emollient simultaneously — particularly valuable for steroid-thinned skin
  • Safety precaution: Test temperature with the caregiver's wrist before application — steroid-thinned skin has reduced heat tolerance; reduce temperature to 48–50°C if skin is fragile
  • Heated blankets for morning stiffness: Apply for 20–30 minutes upon waking to reduce the morning stiffness that characterizes inflammatory arthritis; electric blankets on low setting or microwavable heat packs
  • Warm compresses for knee/hip contractures: Moist heat applied before and during repositioning reduces the mechanical pain of moving contracted joints
No drug interactions. No renal or hepatic burden. Compatible with the full immunosuppressive regimen. A comfort intervention that families can deliver independently after training. Combines well with the SSc hand management protocol from Card #59.[36][38]
S08Everyone

Natural & Herbal Options

Evidence grading, dosing where supported, drug interaction flags, and explicit contraindications specific to this diagnosis. Patients will use supplements — this section helps you have the right conversation.

From the Field
Waldo Rios, NP
Hospice NP · 12+ Years
"Severe rheumatoid arthritis and systemic lupus erythematosus create a supplement safety landscape defined by four simultaneous concerns: (1) immunosuppression amplification — many supplements marketed as 'immune-boosting' or 'anti-inflammatory' may interfere with the careful immune suppression that controls the disease; conversely, supplements with immunostimulatory properties may trigger flares in autoimmune disease; (2) drug interactions with the complex RA/SLE medication regimen — methotrexate, hydroxychloroquine, warfarin for APS, corticosteroids, and biologics all have specific supplement interactions; (3) organ-specific toxicity amplification — the kidneys, liver, and bone marrow that have been compromised by decades of immunosuppressive therapy have reduced tolerance for supplements that add further burden; and (4) the NSAID-renal interaction in patients with lupus nephritis CKD — supplements with any NSAID-like activity add to the renal risk. The most dangerous statement in the RA/SLE supplement conversation: 'I take it because it's natural and it helps my inflammation.' In a disease managed by precise immune modulation, adding an uncharacterized immune-modulating supplement to a carefully constructed medication regimen can destabilize the entire therapeutic balance. Every supplement must be assessed against the specific immunosuppressive regimen and the specific organ damage profile."
— Waldo, NP · Terminal2
Herb / Supplement Evidence Grade Typical Dose Potential Benefit ⚠ Interactions / Contraindications
Vitamin D₃ (Cholecalciferol) Grade A 2,000–4,000 IU daily for documented deficiency; calcium 1,000–1,200 mg/day divided (timed separately from bisphosphonates) Addresses steroid-induced osteoporosis by correcting impaired calcium absorption, reducing secondary hyperparathyroidism, and supporting osteoblast function. Musculoskeletal comfort from correcting deficiency-related myalgia. Immune modulation benefit documented in RA and SLE — low vitamin D correlates with disease activity.[39] Monitor 25-OH vitamin D levels — target 30–50 ng/mL; avoid hypercalcemia in patients with granulomatous disease or renal failure; calcium timing with bisphosphonate (separate by 2 hours); no significant interaction with methotrexate, hydroxychloroquine, or biologics at these replacement doses. In ESRD (eGFR <15), use active form calcitriol instead — native vitamin D cannot be hydroxylated by failing kidneys.[40]
Omega-3 Fatty Acids (EPA + DHA) Grade B 2–3 g EPA+DHA daily (fish oil capsules or liquid); take with food for absorption Multiple RCTs specifically in RA demonstrate reduced morning stiffness duration, lower joint tenderness counts, and reduced NSAID requirement. Anti-inflammatory mechanism via prostaglandin competition (increased PGE3 production displacing pro-inflammatory PGE2). The most evidence-supported supplement in RA with a specific disease mechanism.[45] At standard doses (2–3 g/day), antiplatelet effect is not clinically significant in most patients. However, in patients anticoagulated for APS (INR 2–3), any additional antiplatelet activity increases bleeding risk — monitor INR more frequently when initiating. Minimal renal clearance concern at these doses in lupus nephritis CKD. No significant interaction with methotrexate, hydroxychloroquine, or corticosteroids. May cause GI upset — take with meals.[37]
Topical Capsaicin Cream Grade B 0.025–0.1% cream applied to accessible joints (knees, MCPs) 3–4 times daily; initial burning diminishes over 1–2 weeks Depletes substance P from peripheral nociceptors through TRPV1 receptor activation and subsequent desensitization. RCT evidence demonstrates pain reduction in osteoarthritis and RA when applied to accessible joint surfaces. Particularly useful for localized pain in patients who cannot tolerate additional systemic analgesics.[46] No systemic absorption at topical doses. No interaction with the immunosuppressive regimen. No renal or hepatic toxicity. Do NOT apply to inflamed, broken, or steroid-thinned fragile skin (assess skin integrity before recommending). Apply with gloves — accidental eye contact causes severe burning. Initial burning at application is the primary limitation; warn patient and family that this diminishes with consistent use.[38]
Turmeric / Curcumin (dietary doses) Grade C Dietary doses from cooking (turmeric in food) — NOT high-dose supplement capsules above 1,000 mg/day Anti-inflammatory activity through NF-κB inhibition demonstrated in preclinical models and small RCTs in RA. At dietary doses from food, the safety profile in RA/SLE is acceptable. May provide modest additive anti-inflammatory comfort when used in cooking.[46] Critical distinction: dietary turmeric is safe; high-dose supplement curcumin is not. At high doses (>1,000 mg/day), CYP3A4 inhibition alters corticosteroid metabolism and calcineurin inhibitor levels. Antiplatelet activity at high doses interacts with warfarin for APS anticoagulation — may increase INR unpredictably. Distinguish dietary use (safe) from supplement use (requires drug interaction assessment). Document the distinction explicitly when counseling.[45]
Probiotics (Lactobacillus / Bifidobacterium) Grade C Multi-strain probiotic with Lactobacillus and Bifidobacterium species; dose varies by preparation — follow manufacturer guidance Emerging evidence in RA for gut microbiome modulation affecting systemic inflammation. Small RCTs in RA demonstrate modest improvement in DAS28 scores and inflammatory markers. May improve GI tolerability of the medication regimen (methotrexate GI side effects, NSAID gastropathy). Addresses the gut dysbiosis documented in RA patients.[46] Caution in severely immunosuppressed patients: Rare cases of Lactobacillus bacteremia reported in immunocompromised hosts. In patients on two or more immunosuppressants with severe lymphopenia (<400 cells/μL), the theoretical risk of probiotic bacteremia exists. Avoid live organism probiotics in patients with central venous catheters or severe mucositis. No significant drug interactions with the standard RA/SLE regimen at normal doses.[22]
Magnesium Glycinate Grade C 200–400 mg elemental magnesium daily (glycinate form preferred for GI tolerability) Addresses the hypomagnesemia that is common in patients on chronic corticosteroids (renal magnesium wasting) and on PPIs (reduced GI absorption). May reduce muscle cramps, improve sleep quality, and provide modest benefit for the neuropathic pain component. The glycinate form is better tolerated than magnesium oxide.[39] Dose-reduce in lupus nephritis CKD — magnesium accumulates in renal failure (eGFR <30: reduce to 100–200 mg/day or avoid; monitor serum magnesium). May reduce absorption of some antibiotics (tetracyclines, fluoroquinolones) — separate by 2 hours. No significant interaction with methotrexate, hydroxychloroquine, or corticosteroids. The laxative effect of magnesium oxide can be beneficial or problematic — glycinate form has less GI effect.[40]
Evening Primrose Oil (GLA) Grade C 1,000–3,000 mg daily (providing 240–720 mg gamma-linolenic acid/GLA) Gamma-linolenic acid (GLA) is converted to DGLA which competes with arachidonic acid in the prostaglandin pathway. Small RCTs in RA demonstrate reduced morning stiffness and joint tenderness. Anti-inflammatory mechanism is distinct from omega-3s — the two can be used together for complementary prostaglandin modulation.[45] GLA has mild antiplatelet activity — same warfarin interaction caution as omega-3s in APS patients. May lower seizure threshold at high doses — use with caution in NPSLE seizure patients on anticonvulsants. No significant hepatic or renal toxicity at standard doses. May cause mild GI upset. No interaction with methotrexate or hydroxychloroquine.[37]
Melatonin Grade C 1–5 mg at bedtime for sleep disruption from chronic pain and steroid-induced insomnia Addresses the sleep disruption that is pervasive in RA/SLE — chronic pain, steroid-induced insomnia (corticosteroids cause insomnia through central excitatory effects), and anxiety about disease progression. Emerging evidence for anti-inflammatory and immunomodulatory properties that may complement the anti-inflammatory regimen. Low toxicity profile.[46] Theoretical immunomodulatory concern: Melatonin has immunostimulatory properties in some models — may theoretically promote autoimmune flares in susceptible patients, though clinical reports of this are rare. Use with caution and monitor for disease flare signs (increased joint swelling, rising anti-dsDNA). No significant hepatic or renal toxicity. May enhance the sedative effects of gabapentinoids and opioids — start at low dose. No significant interaction with warfarin, methotrexate, or hydroxychloroquine.[45]
🚫 Avoid in Severe RA / SLE
  • Echinacea, Elderberry, Astragalus, Cat's Claw — all immune-stimulating supplements: The class of supplements marketed for "immune support" is specifically contraindicated in autoimmune disease. Their mechanism of action — stimulating the immune system — is the opposite of what RA/SLE management requires. The immune system that has been carefully suppressed by methotrexate, hydroxychloroquine, and biologics to prevent synovitis and organ attack can be restimulated by these supplements, producing disease flares. Address directly with patients: "In autoimmune disease, the problem is that the immune system is already overactive. The medications you take calm it down. Immune-boosting supplements work in the opposite direction and can trigger a flare."[45]
  • High-dose Vitamin C (>500 mg/day) in lupus nephritis CKD (eGFR <30): Vitamin C is metabolized to oxalate, which accumulates in renal failure — the same oxalate nephropathy concern from Card #47. In patients with lupus nephritis ESRD, high-dose vitamin C accelerates oxalate crystal deposition in the kidneys and systemically. Low doses (100–250 mg/day) from dietary sources are acceptable; high-dose supplements are contraindicated.[23]
  • St. John's Wort (Hypericum perforatum): Potent CYP3A4 inducer that reduces levels of cyclosporine, tacrolimus, and other calcineurin inhibitors used in severe SLE management — can cause acute organ rejection in renal transplant patients or disease flare from sub-therapeutic immunosuppressant levels. Also reduces warfarin levels (critical in APS anticoagulation — can precipitate thrombosis from sub-therapeutic INR). Also reduces methotrexate efficacy. Absolutely contraindicated in any patient on cyclosporine, tacrolimus, warfarin, or methotrexate.[43][26]
  • Willow Bark (Salix alba — contains salicin/salicylate) in lupus nephritis CKD: Willow bark contains salicylate, which has the same COX-inhibiting mechanism as aspirin and pharmaceutical NSAIDs. In patients with lupus nephritis and eGFR below 30, the same absolute NSAID contraindication applies to this herbal form. Patients and families who have been told to avoid NSAIDs may not realize that "natural" willow bark is the same pharmacological class. Address this explicitly: willow bark IS an NSAID in herbal form.[37]
  • High-dose Boswellia serrata in lupus nephritis CKD: Boswellic acids have COX and 5-LOX inhibitory activity — an NSAID-like mechanism. At high supplement doses, the same renal concerns as pharmaceutical NSAIDs apply in patients with eGFR below 30. Low dietary doses may be tolerable, but high-dose supplements marketed for "joint inflammation" carry the same renal risk as ibuprofen in this population.[37]
  • High-dose Zinc (>30 mg/day) in patients on penicillamine: Penicillamine (D-penicillamine), occasionally used in RA, forms chelates with zinc — reducing both zinc absorption and penicillamine efficacy. If the patient is still on penicillamine, high-dose zinc supplementation reduces its therapeutic level. Check the medication list for penicillamine before recommending zinc supplements. Standard multivitamin zinc (15 mg) is generally acceptable; therapeutic zinc doses (>30 mg) are not.[44]
  • Alfalfa (Medicago sativa): Contains L-canavanine, a non-protein amino acid that has been shown to reactivate SLE in primate models and is associated with lupus flares in case reports. Specifically contraindicated in SLE patients. Often found in "green superfood" powder blends — check ingredient labels.[45]
S09Everyone

Timeline Guide

The RA/SLE end-stage timeline — from decades of disease accumulation through hospice enrollment to final hours.

The trajectory of severe RA and SLE toward hospice is unlike any other diagnosis in palliative medicine. It is not the weeks-to-months decline of metastatic cancer or the stepwise crises of heart failure — it is the decades-long accumulation of inflammatory damage and treatment toxicity that slowly erodes every system the disease touches and every system the medications burden. The patient enrolling in hospice from severe RA or SLE has typically carried their disease for 15–30 years before the end-organ damage burden crosses the hospice-eligible threshold.[1] The terminal phase is determined by which organ system fails first: lupus nephritis progressing to ESRD (apply Card #47), RA-ILD producing respiratory failure (apply Card #43), accelerated atherosclerosis producing cardiovascular death, or overwhelming infection in the immunosuppressed host (apply Card #54). This timeline reflects the specific disease history of a population that arrives at hospice exhausted from decades of fighting.[2]

YRS
The Decades-Long Disease History (15–30 Years Before Hospice)
  • Onset of the first joint symptoms (RA: symmetric small-joint synovitis of the hands and wrists) or the first butterfly rash and fatigue (SLE); diagnosis confirmed by a rheumatologist using ACR/EULAR classification criteria[3]
  • Years of medication adjustments — methotrexate, hydroxychloroquine, sulfasalazine, leflunomide, then escalation to biologics (anti-TNF agents, rituximab, belimumab) and corticosteroids at doses ranging from 5 mg/day maintenance to 60 mg/day for acute flares[4]
  • Recurrent disease flares producing temporary worsening — each flare leaving behind incremental structural damage that does not reverse when inflammation subsides; the RA pannus eroding cartilage and bone; the lupus immune complexes depositing in kidneys, pericardium, and brain[5]
  • Hospitalizations for major complications: lupus nephritis Class III–IV, pericarditis/pleuritis, PCP or other opportunistic infections from immunosuppression, RA-ILD exacerbations[6]
  • Medication complications accumulating in parallel: avascular necrosis (hip pain from steroid-induced osteonecrosis), osteoporotic vertebral compression fractures from steroid-thinned bone, hepatic fibrosis from cumulative methotrexate, cushingoid features (moon face, weight gain, buffalo hump, thinning skin that bleeds easily) from years of prednisone[7]
  • Functional losses accumulating: swan neck and boutonnière deformities of the fingers, ulnar deviation of the MCP joints, elbow and knee flexion contractures; the ability to button a shirt, open a jar, and eventually drive — all lost incrementally[8]
  • The patient arriving at this phase has been managing a complex chronic disease while working, parenting, and building a life around the accommodations that autoimmune disease demands — they are not naive about their disease; they are exhausted from it
MOS
Approaching Hospice Eligibility — Accelerating End-Organ Failure (6–12 Months)
  • Lupus nephritis progresses to ESRD despite mycophenolate and rituximab — eGFR declining below 15 mL/min, dialysis initiated or the conversation about dialysis withdrawal begins; apply Card #47 ESRD framework[9]
  • RA-ILD produces progressive oxygen dependence — new supplemental O₂ requirement, declining FVC, CT chest showing progressive fibrosis (apply Card #43 ILD framework)[10]
  • Cardiovascular event from accelerated atherosclerosis — MI, stroke, or progressive heart failure from RA/SLE-associated cardiomyopathy; SMR 1.5–2.0 for RA, 2.4+ for SLE[11]
  • Recurrent PCP or other serious opportunistic infections despite prophylaxis — the immunosuppression that controlled the disease now producing life-threatening infections with increasing frequency[12]
  • Functional status declines below PPS 40% — bed-bound or chair-bound majority of the day; dependence in all ADLs; joint contractures limiting all self-care
  • The rheumatologist raises the hospice conversation — or the hospitalist after the third admission in three months; the transition from disease-modifying intent to comfort-directed care[13]
  • Hospice enrollment brings a palliative framework to a disease managed in the rheumatology system for decades — the clinical handoff requires understanding the full medication regimen, the organ damage inventory, and the treatment toxicity burden
WKS
Active Hospice Enrollment — Parallel Multi-System Management (Weeks to Months)
  • Atlanto-axial subluxation protocol communicated at enrollment — cervical spine imaging reviewed; if AAI documented (C1-C2 distance >3 mm), cervical collar placed and restriction posted in patient's room before any care is delivered[14]
  • Corticosteroid minimum physiological dose established — taper plan from current dose to 5–7.5 mg/day prednisone equivalent documented; adrenal insufficiency risk communicated to all covering clinicians[15]
  • PCP prophylaxis verified or started — TMP-SMX SS daily or dapsone 100 mg daily (with G6PD check in appropriate populations); prescription written at enrollment visit[12]
  • Joint contracture positioning protocols initiated — web space padding for hand contractures, positioning wedges for hip and knee contractures, pressure injury prevention at contracted joints[8]
  • Five-component pain management assessed and established: (1) scheduled acetaminophen for structural nociceptive pain, (2) opioid for moderate-to-severe structural and visceral pain, (3) gabapentinoid for neuropathic pain, (4) NSAID for serositis (if eGFR >30), (5) corticosteroid for inflammatory pain[16]
  • ESRD framework from Card #47 applied if lupus nephritis dialysis is present; APS anticoagulation comfort-benefit reassessed; NPSLE seizure management plan documented; advance directive completed with RA/SLE-specific decisions[9]
  • Rheumatologist engaged as continuing clinical partner for complex medication decisions and disease-specific guidance through the hospice course
DAYS
Terminal Transition — Multi-Organ Failure Convergence (Days to Weeks)
  • The dominant organ system that fails first determines the terminal trajectory: ESRD — apply Card #47 post-withdrawal timeline; respiratory failure from RA-ILD or lupus pneumonitis — apply Card #43; cardiovascular failure from lupus cardiomyopathy — heart failure trajectory; sepsis from opportunistic infection — apply Card #54[17]
  • Functional status below PPS 20% — bed-bound, minimal oral intake, sleeping most of day; progressive obtundation if uremia from ESRD or NPSLE cognitive decline[18]
  • Comfort medications titrated to dominant symptom burden — morphine or fentanyl for pain and dyspnea; midazolam for agitation; glycopyrrolate for secretions
  • Corticosteroid physiological replacement dose maintained throughout the terminal phase — the minimum prednisone dose continues via rectal or parenteral route if oral route is lost; hydrocortisone 100 mg IM available in comfort kit[15]
  • Anticoagulation for APS reassessed — if actively dying and bleeding risk exceeds thrombosis benefit, warfarin discontinued with explicit documentation of the clinical rationale[19]
  • Family teaching intensified: what the dying process looks like from multi-organ autoimmune failure; what the medications are doing; what the next hours to days will bring
HRS
Final Hours
  • Cheyne-Stokes or agonal respirations; mandibular breathing; mottling of knees and feet; peripheral cyanosis — the common final pathway regardless of which organ system failed first[18]
  • Unresponsive or minimally responsive — auditory awareness may persist; family directed to continue speaking, touching, and being present
  • Seizure risk if NPSLE — diazepam rectal gel 10–20 mg or midazolam 5 mg buccal/SQ accessible at bedside; family trained on seizure first aid before this phase[20]
  • Adrenal crisis risk if corticosteroid missed — hydrocortisone 100 mg IM available; if patient cannot take oral prednisone and no IV/IM access has been established, contact hospice nurse immediately
  • Terminal secretions managed with glycopyrrolate 0.2 mg SQ q4h or hyoscine patch — family prepared for the sound; "this is the body's natural process — your person is not choking or drowning"
  • The death that comes after decades of autoimmune disease carries a specific dignity — a person who never stopped fighting a disease that attacked everything it could reach, managed with the same precision at the end that their disease's complexity demanded from the beginning
S10Clinician

Medications to Anticipate

RA/SLE-specific medication management at hospice — corticosteroid protocols, multi-mechanism pain targeting, and the three non-negotiable safety priorities.

RA/SLE medication management at hospice enrollment requires the most complex pharmacological assessment in all of rheumatological hospice care. The patient arrives with a medication regimen built over decades — immunosuppressants, corticosteroids, biologics, anticoagulants, analgesics, gastroprotectives — each prescribed for a specific disease manifestation by a rheumatology team that has managed the disease for years. The hospice clinician's task is not to simplify this list reflexively but to assess each medication against the comfort-benefit framework while maintaining three non-negotiable safety priorities.[4]

🚨 Three Non-Negotiable Safety Priorities at Enrollment

(1) THE CORTICOSTEROID PHYSIOLOGICAL REPLACEMENT DOSE CANNOT BE STOPPED — calculate the minimum dose (prednisone 5–7.5 mg/day equivalent) and establish the taper plan from the current dose to this minimum. Document the adrenal insufficiency risk at the top of the medication list with the same prominence as morphine in ESRD.[15]

(2) THE ATLANTO-AXIAL SUBLUXATION CERVICAL COLLAR PROTOCOL — if documented on cervical imaging, communicate to every caregiver before any care is provided. Post the restriction in the patient's room. No neck hyperflexion under any circumstance.[14]

(3) PCP PROPHYLAXIS STATUS — assess at enrollment. If the patient is on significant immunosuppression (prednisone >20 mg/day, two or more immunosuppressants, or prior PCP history) without prophylaxis, start TMP-SMX or dapsone at enrollment. Write the prescription before you leave the first visit.[12]

Beyond these three safety acts: the pain management plan must address all five mechanisms simultaneously; the ESRD framework from Card #47 applies if lupus nephritis ESRD is present; the APS anticoagulation requires explicit comfort-benefit reassessment.[16]

DrugClass / Target SymptomStarting DoseNotes / Cautions
Prednisone Corticosteroid / HPA Axis Replacement + Anti-inflammatory Comfort 5–7.5 mg PO daily (minimum physiological dose) THE CORTICOSTEROID THAT CANNOT BE STOPPED. This dose prevents adrenal insufficiency and provides baseline anti-inflammatory comfort for joint and systemic inflammatory pain. Taper from current dose to this minimum over weeks. Administer with food. Continue the PPI for gastroprotection. If patient cannot take oral: hydrocortisone 100 mg IM for emergency adrenal supplementation. ⚠ NEVER discontinue abruptly — addisonian crisis risk.[15]
Document minimum dose and taper schedule at top of medication safety alerts.
Acetaminophen Non-opioid Analgesic / Structural Nociceptive Pain 500–1000 mg PO q6h scheduled Foundation of RA/SLE pain management — structural nociceptive pain from joint destruction, avascular necrosis, and compression fractures. Scheduled, not PRN (Husebo framework). Liquid formulation for patients with severe hand contractures who cannot manage pills. Rectal suppository when oral route is lost.[16]
Max 3 g/day if hepatic fibrosis from methotrexate; 2 g/day if significant hepatic impairment.
Morphine SR / Oxycodone SR Opioid / Moderate-to-Severe Structural & Visceral Pain Morphine SR 15–30 mg PO q12h (titrate to effect) Opioid for nociceptive pain exceeding acetaminophen capacity — joint destruction, avascular necrosis, pathological fractures, serositis. Calibrate to patient's established effective dose. ⚠ In lupus nephritis ESRD (eGFR <30): fentanyl preferred — morphine's active metabolites accumulate. Apply Card #47 opioid safety framework.[21]
Breakthrough: morphine IR 5–10 mg PO q2h PRN or fentanyl SL if renal impairment.
Gabapentin Gabapentinoid / Neuropathic Pain 300–900 mg PO TID Neuropathic pain from vasculitic peripheral neuropathy (RA or SLE), methotrexate neurotoxicity, or ischemic neuropathy from APS. Targets the burning, shooting, electric pain component that opioids alone cannot address.[22] ⚠ Dose-adjust for lupus nephritis CKD: eGFR 15–29 → max 300 mg/day; eGFR <15 → max 150 mg/day.
Start low (100 mg TID), titrate over 1–2 weeks. Document specific neuropathic pain mechanism.
Naproxen / Ibuprofen NSAID / Serositis & Inflammatory Joint Pain Naproxen 500 mg PO BID or Ibuprofen 400–800 mg PO TID The most effective analgesics for serositis pain (pleuritis, pericarditis) because the mechanism is prostaglandin-mediated. Also for inflammatory joint pain above baseline corticosteroid management. ⚠ ABSOLUTE CONTRAINDICATION if eGFR <30 — use corticosteroids as alternative anti-inflammatory for serositis. Check renal function before every prescription.[23]
Must co-prescribe PPI. Document renal function and serositis/inflammatory pain indication.
TMP-SMX SS Antimicrobial / PCP Prophylaxis 1 SS tablet (80/400 mg) PO daily The most important antimicrobial prescription at enrollment for any patient on significant immunosuppression. Continue throughout the immunosuppressed state. A comfort medication — PCP is among the most distressing infections in terms of dyspnea burden.[12] ⚠ Check for sulfa allergy. Monitor for cytopenias (especially with methotrexate co-administration).
Alternatives: dapsone 100 mg PO daily (check G6PD first) or atovaquone 1500 mg PO daily.
Hydroxychloroquine DMARD / SLE Flare Protection & Anti-inflammatory 200–400 mg PO daily The most protective DMARD in SLE — documented reduction in flares, organ damage accumulation, and mortality. Safe and non-immunosuppressive enough to continue through end-stage without significant infection risk. One of the few DMARDs where hospice continuation is clearly justified.[24]
Retinal toxicity concern deprioritized at hospice if prognosis is months. Document SLE flare protection and comfort-directed continuation rationale.
Warfarin Anticoagulant / Antiphospholipid Syndrome Dose to INR target: 2.5–3.5 (arterial) or 2–3 (venous only) APS anticoagulation — arterial thrombosis requires INR 2.5–3.5; venous only requires INR 2–3. Assess comfort-benefit at enrollment against bleeding risk (thrombocytopenic lupus, renal platelet dysfunction). ⚠ DOACs NOT recommended for APS with triple positivity or arterial events (TRAPS trial). Warfarin specifically indicated.[19]
Document APS indication, INR target, monitoring plan, and explicit comfort-benefit decision.
Omeprazole PPI / Gastroprotection 40 mg PO daily Gastroprotection for dual NSAID-corticosteroid exposure — the PPI that reduces gastric bleeding risk from decades of combined use. Continue at hospice enrollment. Essential in any patient on concurrent corticosteroid and NSAID therapy.[25]
If on clopidogrel: use pantoprazole instead (less CYP2C19 interaction).
Levetiracetam Anticonvulsant / NPSLE Seizures 500–1000 mg PO BID NPSLE seizure prophylaxis — anticonvulsant continuation is a comfort-directed medication in patients with documented neuropsychiatric SLE seizures. Fewer drug interactions than older anticonvulsants; does not require frequent blood level monitoring.[20]
Advance directive should address seizure management preference. Dose-adjust if eGFR <30.
Midazolam Benzodiazepine / Acute Pain Crisis & Terminal Agitation 2.5–5 mg SQ/IM PRN or 1–2.5 mg/hr CSCI Acute severe joint pain crisis, serositis crisis, or terminal agitation management. Drawn and accessible from the first visit. For CSCI: titrate to comfort during terminal phase.[26]
Also indicated for seizure first aid if diazepam rectal gel unavailable: midazolam 5 mg buccal/SQ.
Lorazepam Benzodiazepine / Anxiety & Dyspnea Adjunct 0.5–1 mg PO/SL q4–6h PRN Anxiety component of chronic pain and disease-related distress. Adjunctive for dyspnea in RA-ILD. Sublingual route available when oral is impaired.[26]
Avoid scheduled long-term use; reassess need at each visit.
Glycopyrrolate Anticholinergic / Terminal Secretions 0.2 mg SQ q4h PRN Reduces terminal secretions without CNS effects. Preferred over hyoscine in conscious patients. Begin when secretion sound first appears — earlier initiation is more effective than rescue dosing.[18]
Fentanyl Patch Opioid / Pain (Renal-Safe Alternative) 12–25 mcg/hr transdermal q72h (titrate from oral opioid equivalent) Preferred long-acting opioid in lupus nephritis ESRD (eGFR <30) — no active metabolites requiring renal clearance. Convert from oral morphine equivalent using standard conversion tables. Allow 12–24 hours for steady state after application.[21] ⚠ Not for opioid-naive patients. Requires stable pain pattern — not for acute pain titration.
Breakthrough: fentanyl SL 100–200 mcg or oral transmucosal fentanyl PRN.
Paraffin Wax Treatment Non-pharmacological / Hand Contracture Pain & Stiffness 15–20 minutes daily (metered-dose paraffin bath) Heat therapy for RA hand contractures — reduces morning stiffness, contracture pain, and improves tolerance of range-of-motion and personal care activities. Prescribe as formal comfort treatment, not a suggestion. Family instructed in technique.[27]
Same approach as in SSc Card #59. Contraindicated over open wounds or active skin breakdown.
Hydrocortisone IM Emergency Corticosteroid / Adrenal Crisis Prevention 100 mg IM (pre-drawn syringe at bedside) Emergency adrenal supplementation when oral prednisone cannot be taken (vomiting, obtundation, oral route lost). Pre-drawn and labeled at bedside from enrollment. Instruct family: if patient vomits prednisone dose or cannot swallow, administer IM and call hospice nurse immediately.[15] ⚠ This is a safety medication, not optional — adrenal crisis can be fatal.

🚨 Comfort Kit Must-Haves for Severe RA / SLE

The RA/SLE comfort kit addresses four simultaneous clinical scenarios unique to this diagnosis:

  • (1) Atlanto-axial subluxation safety protocol — cervical collar labeled and positioned beside the patient's bed. Posting in the patient's room: "DO NOT FLEX NECK — C1-C2 SUBLUXATION DOCUMENTED — COLLAR FOR ALL REPOSITIONING AND TRANSFERS."[14]
  • (2) Corticosteroid crisis kit — if the patient is nauseated/vomiting and cannot take oral prednisone: hydrocortisone 100 mg IM (syringe pre-drawn and labeled) for emergency adrenal supplementation. Instruction card for family: "If prednisone dose is vomited or cannot be swallowed → administer this injection in the outer thigh → call hospice nurse immediately."[15]
  • (3) Acute serositis crisis kit — naproxen 500 mg (if eGFR >30) and breakthrough opioid (morphine IR 10–15 mg or fentanyl SL) for the pleuritic or pericarditic pain of acute lupus serositis; if renal impairment, substitute prednisone 20 mg single dose as anti-inflammatory alternative[23]
  • (4) NPSLE seizure kit — advance directive decision about seizure management accessible at bedside; diazepam rectal gel 10–20 mg or midazolam 5 mg buccal/SQ for seizure first aid; family trained on seizure first aid: protect from injury, do not restrain, administer rescue medication, time the seizure, call hospice[20]
S11Clinician

Clinician Pointers

High-yield clinical pointers for the RA/SLE hospice team — the specific assessments, safety acts, and clinical intelligence that decades of autoimmune disease complexity demands.

1
Read the cervical spine MRI before touching the patient's neck — this is the most specific clinical safety act in RA hospice
If atlanto-axial subluxation is documented (C1-C2 distance >3 mm on lateral cervical spine imaging), the cervical collar must be applied before any repositioning, personal care, or transfer. Communicate the restriction to every caregiver — aide, family member, covering nurse — before any care is delivered. Post the restriction in the patient's room where it cannot be missed. Document AAI in the first line of the care plan safety alerts. The aide who provides morning care without knowing about AAI has been set up by a clinical system that did not communicate the most dangerous positioning restriction in the care plan. Neck hyperflexion in a patient with documented AAI can produce acute spinal cord compression, tetraplegia, or death. This is preventable with a single act: find the imaging, read it, and communicate the finding before anyone touches the patient's neck.[14]
2
Calculate the minimum corticosteroid dose at enrollment and document it as the first medication safety note
The patient who has been on prednisone for 25 years has a suppressed HPA axis that cannot replace the cortisol the prednisone was providing. Stopping the prednisone to "simplify the medication list" will produce addisonian crisis — hypotension, nausea, vomiting, cardiovascular collapse. Calculate 5–7.5 mg/day prednisone equivalent as the minimum physiological replacement dose. Taper from the current dose (which may be 15–20 mg/day or higher) to this minimum over weeks. Write "NEVER STOP PREDNISONE — ADRENAL INSUFFICIENCY RISK — MINIMUM DOSE 5 MG/DAY" in the medication safety section where it cannot be missed. Communicate to every covering clinician. The 2 AM covering nurse who stops the prednisone while simplifying the medication list has caused a potentially fatal error. Prevent it with documentation.[15]
3
Assess PCP prophylaxis status at enrollment and start it at the first visit if not present
Ask: is this patient on TMP-SMX or dapsone? If not, why not? In any patient on prednisone above 20 mg/day, on two or more immunosuppressants, or with a prior PCP history, prophylaxis should be started at enrollment. Write the prescription before you leave. The PCP that develops in an unprotected immunosuppressed hospice patient is a preventable clinical failure. PCP produces severe dyspnea — one of the most distressing symptoms in hospice — and carries high mortality in the immunocompromised host. Prevention with a single daily TMP-SMX SS tablet is a comfort-directed intervention. If sulfa allergy: dapsone 100 mg daily (check G6PD first in Black and Mediterranean patients) or atovaquone 1500 mg daily.[12]
4
Assess and document hand contracture web space status at every visit
Lift the fingers if possible and examine the web spaces. Document any maceration, erythema, candidal infection, or skin breakdown. This is a pressure injury risk that standard protocols miss because they do not examine contracted web spaces — the fingers are closed, the web spaces are invisible, and the maceration progresses silently under the contracted hand. Apply cotton gauze padding in the web spaces to separate skin surfaces and prevent moisture damage. Miconazole powder for any evidence of candidal infection (satellite lesions, bright erythema). The contracted RA hand that develops a web space wound has a wound that is extremely difficult to heal because the contracture cannot be released. Prevention at every visit is the clinical standard.[8]
5
Address the decades of disease and the steroid body directly — ask the patient about their changed body
The patient who has been living with moon face, weight gain, thinning skin, and the visible deformities of RA or lupus for 25 years has a specific relationship with their body that deserves clinical acknowledgment. Ask: "How has this disease changed your body over the years? What has been hardest about living in this body?" The hospice nurse who says "I see what this disease has done to your body over these years" is saying something that may have never been said in 25 years of rheumatology appointments. This is not small talk — it is a clinical assessment of body image distress, decades of grief over functional and appearance losses, and the cumulative emotional weight of a disease that changed how they look to the world. Document the response and refer to social work and chaplaincy for deeper exploration.[28]
6
Assess APS anticoagulation at enrollment with the same rigor as opioid selection
Ask: What is the APS history — arterial thrombosis (stroke, MI, peripheral arterial) versus venous only (DVT, PE)? What is the current INR? What is the bleeding risk — is there thrombocytopenic lupus? Renal failure platelet dysfunction? Is the patient on concurrent NSAID therapy adding GI bleeding risk? Document the explicit comfort-benefit decision for continuing or reassessing the warfarin. Arterial APS requires INR 2.5–3.5; venous-only APS requires INR 2–3. The TRAPS trial demonstrated that DOACs (rivaroxaban) are inferior to warfarin in APS with triple antibody positivity — do not switch to a DOAC for "convenience." The APS patient whose warfarin is stopped without a documented risk-benefit analysis has been left unprotected against a thrombotic event that produces more suffering than the anticoagulation it required.[19]
7
Assess the five pain mechanisms at every visit — not just "rate your pain 0–10"
The chronic pain of severe RA/SLE is mechanistically complex — five simultaneous pain generators requiring five distinct pharmacological approaches: (1) inflammatory pain from active synovitis or serositis → corticosteroids, NSAIDs; (2) neuropathic pain from vasculitic neuropathy or medication neurotoxicity → gabapentinoids; (3) structural nociceptive pain from joint destruction, AVN, fractures → acetaminophen, opioids; (4) visceral pain from pericarditis or pleuritis → NSAIDs (if renal safe), opioids; (5) central sensitization and fibromyalgia overlap → duloxetine, pregabalin. The numeric pain scale alone tells you nothing about which mechanism is flaring. Ask: "Is the pain burning or shooting? Is it in the joints or the chest? Is it worse with movement or at rest? Is it the same pain or a new pain?" Each answer directs a specific intervention.[16]
8
Know the SLE health disparity — Black women with SLE die younger from more severe disease with less access to timely care
SLE disproportionately affects Black women — incidence approximately 3:1 Black-to-white ratio, with earlier onset, more severe lupus nephritis, higher rates of ESRD, and worse outcomes at every stage. The standardized mortality ratio in Black women with SLE exceeds 3.0. The Black woman dying from SLE at age 42 has likely experienced the healthcare disparities documented throughout the SLE research literature: later diagnosis, less consistent specialty access, more advanced organ damage at presentation, and higher rates of treatment non-adherence driven by cost barriers, transportation barriers, and provider mistrust rooted in legitimate historical and ongoing experiences of medical racism. The hospice clinician's role is not to fix systemic racism in one enrollment visit — it is to provide the same quality of care, the same respect, and the same clinical precision regardless of race, and to explicitly acknowledge when disparities have shaped the clinical trajectory. Ask: "Has getting care for this disease always been easy?" The answer will tell you what this patient has been carrying beyond the disease itself.[29]
9
Reassess every immunosuppressant against the comfort-benefit question at enrollment — do not reflexively continue the biologic
The biologic that reduced joint inflammation meaningfully five years ago may be adding infection risk, IV infusion burden, and high cost without providing comfort benefit at end stage. At enrollment, reassess each immunosuppressive agent individually: Does methotrexate at 15 mg/week still serve comfort? (Likely not — adding hepatotoxicity and immunosuppression without proportional symptom relief in a patient with end-stage structural damage.) Does the adalimumab infusion every two weeks still serve comfort? (The answer depends on whether the patient still has active inflammatory pain that responds to TNF inhibition versus structural damage pain that will not respond.) Does hydroxychloroquine serve comfort? (Yes — low toxicity, documented mortality benefit in SLE, and non-immunosuppressive enough to be safe.) Each medication gets an explicit comfort-benefit assessment documented in the care plan. The goal is precision, not simplification for its own sake.[30]
10
Engage the rheumatologist as a continuing clinical partner — they have known this patient longer than you will
The rheumatologist who has managed this patient's RA or SLE for 15–25 years carries institutional knowledge about the disease trajectory, the medication responses, the flare patterns, and the patient's coping style that no chart review can replicate. Reach out at enrollment. Ask for the clinical narrative: What has this disease done to this patient? Which organs are most damaged? What medications worked and which failed? What are the specific complications we should anticipate? Most rheumatologists are relieved to be asked and grateful that hospice is engaging their expertise rather than discarding the complex medication regimen they built over decades. The rheumatologist-hospice partnership produces better medication decisions, better symptom management, and better care for a patient whose disease demands the collaboration.[13]
11
Position for the contracture — not against it
The contracted RA joint that has been in fixed flexion for years cannot be forced into extension without causing pain, tissue damage, or fracture. The positioning protocol must accommodate the contracture, not fight it. Hip and knee flexion contractures require positioning wedges that support the contracted angle — not attempts to straighten the limb. Elbows frozen at non-functional angles need padding at pressure points specific to the contracture position. The aide who attempts to straighten contracted fingers for hygiene without specific training on RA contracture management has caused harm. Train every caregiver: these joints do not move to standard positions. Your job is to make the position they are in as comfortable and skin-safe as possible. Document the specific contracture pattern (which joints, degree of fixed deformity) and the individualized positioning protocol at enrollment.[8]
12
Prepare the family for the specific dying process of multi-organ autoimmune failure — it is not one disease, it is several
The family of the RA/SLE patient needs to understand that their person's body has been under attack from two directions simultaneously — the autoimmune disease and the medications used to control it — for decades. The dying process may involve the convergence of multiple organ system failures at once: kidneys, lungs, heart, and immune defense. Explain which organ system is most likely to fail first in their specific case, what that will look like, and what the hospice team will do about it. Use the specific Card frameworks: "If the kidneys fail further, we will follow the same comfort plan as our kidney disease protocol" (Card #47). "If the lungs become the primary problem, we have a specific plan for managing breathing" (Card #43). The family who understands the map — even a simplified one — tolerates the terrain better than the family who is ambushed by each new crisis.[18]
From the Field
Waldo Rios, NP
Hospice NP · 12+ Years
"The RA patient and the lupus patient have one thing in common that no other hospice diagnosis has — they've been fighting their disease longer than most of us have been doing this work. When I walk into that room, I'm walking into a 25-year relationship between a person and a disease that has changed everything about their body, their identity, and their life. The least I can do is learn the history before I touch the neck, check the prednisone dose before I simplify the med list, and ask 'what has this been like for you?' before I start the clinical assessment. Respect the decades. They earned it."
— Waldo, NP · Terminal2
S12EveryoneClinician

Psychosocial & Spiritual Care

The decades-long relationship with chronic autoimmune disease, the body changed by both disease and treatment, the exhaustion of lifelong illness management, and the specific grief of Black women with SLE.

The person dying from severe rheumatoid arthritis or systemic lupus erythematosus has been carrying their disease for decades — not months, not a single acute hospitalization, but 15, 20, sometimes 30 years of relentless autoimmune assault on their body and their identity. The psychosocial burden of RA and SLE at end of life is qualitatively different from the acute existential crisis of a new cancer diagnosis; it is the accumulated weight of a lifetime of accommodation, loss, and change that has reshaped the patient's body, their relationships, their self-image, and their capacity for hope.[52] Depression prevalence in RA exceeds 38% and in SLE exceeds 40% — rates two to three times higher than the general population — and these rates are systematically underdiagnosed because clinicians attribute depressive symptoms to "expected" disease burden.[53] The psychosocial assessment at hospice enrollment must account for the decades-long relationship between this person and their disease, the body changes that chronic corticosteroid use and joint destruction have produced, the health disparities that have shaped access to care, and the exhaustion that characterizes the end stage of chronic autoimmune illness.

The hospice clinician who walks into this home walks into a story that is 25 years old. The questions that matter most are not the ones about today — they are the ones about all the years that came before. "What has it been like to manage this disease for so long?" opens a conversation that hundreds of rheumatology appointments never hosted.[54]

Psychological Distress Screening — RA & SLE Specific
Depression in Chronic Autoimmune Disease
Grade B

Screen every RA/SLE patient at enrollment — disease-specific depression drivers require disease-specific assessment.[53]

  • Single-question screen: "Are you depressed?" — validated in terminally ill populations with near-perfect sensitivity when asked directly[55]
  • PHQ-2 → PHQ-9: Score ≥3 on PHQ-2 ("little interest/pleasure" + "feeling down/hopeless") warrants full PHQ-9 assessment
  • RA-specific depression drivers: Chronic uncontrolled pain (the strongest independent predictor of depression in RA); functional disability from joint contractures; loss of hand function affecting independence, identity, and occupation; visible deformity affecting self-image and social participation[52]
  • SLE-specific depression drivers: Neuropsychiatric SLE with organic mood disturbance (anti-ribosomal P antibodies associated with lupus psychosis and depression); corticosteroid-induced mood changes; the unpredictability of flares producing chronic hypervigilance; the burden of a disease that is invisible between flares but devastating during them[40]
  • Mirtazapine 7.5–15 mg QHS: First-line in hospice — addresses depression, insomnia, appetite loss, and nausea simultaneously; faster onset than SSRIs; monitor for excessive sedation in patients already fatigued from disease burden
  • Distinguish depression from the exhaustion of decades of chronic disease: The patient who says "I'm tired of fighting" may be expressing appropriate fatigue, not clinical depression — both deserve attention, but only one warrants pharmacotherapy
Anxiety, Body Image, & Existential Distress
Grade B
  • Body image distress in chronic RA/SLE — the steroid body: The moon face from years of prednisone, the weight gain, the thin skin that bruises and tears easily, the dorsal fat pad, the striae — these are visible markers of decades of treatment that have changed the patient's appearance in ways that everyone sees and no one discusses; the chaplain or social worker who creates explicit space for this conversation — "what has it been like to watch your body change from the medications?" — opens a door that 25 years of rheumatology visits never opened[54]
  • Hand deformity grief in RA: The hands are the most visible, most functional, and most identity-linked body part affected by RA; the progressive ulnar deviation, swan neck deformities, and boutonnière deformities that changed the patient's hands over decades represent losses that are simultaneously functional (can't button a shirt, can't hold a grandchild's hand normally) and symbolic (the wedding ring that no longer fits, the handwriting that became unreadable)
  • Lorazepam 0.5 mg SL PRN for acute anxiety episodes — avoid scheduled benzodiazepines unless breakthrough anxiety is frequent and refractory
  • Dignity therapy: Structured life narrative — particularly valuable in RA/SLE where the patient has decades of disease-fighting story to tell; the narrative reframes the disease years as evidence of resilience rather than loss[55]
  • Refer to social work and chaplaincy at enrollment — not at crisis. The patient who has been managing a chronic disease for 25 years has extensive coping mechanisms that may mask deep distress
Clinical Pearl — The Decades-Long Disease Relationship

"The person who has been fighting RA or SLE for 25 years and is now dying from its complications has a relationship with their disease that is longer than most marriages. They know their disease better than you do — the flare triggers, the medication side effects, the accommodations they've made. The hospice clinician who respects that expertise — who asks 'teach me about your disease' rather than lecturing about it — builds trust faster than any clinical competence demonstration. The question 'what has it been like to manage this for so long?' may be the most therapeutic intervention of the enrollment visit — because no one in 25 years of specialist care has ever asked it."[54]

Spiritual Assessment — RA & SLE Specific

Spirituality in chronic autoimmune disease takes specific forms that generic spiritual assessment tools may miss. The RA/SLE patient has been asking "why me?" for decades — not in the acute existential crisis of a new terminal diagnosis, but in the slow grinding question of a disease that attacked them in their 20s or 30s and never stopped. Use the FICA framework (Faith/beliefs, Importance, Community, Address) with RA/SLE-specific modifications:[55]

  1. 01
    Ask about the meaning of decades of illness: "You've been living with this disease for a very long time. How has it changed what matters most to you?" — This reframes the disease years as a source of wisdom, not only suffering. Many RA/SLE patients have developed profound spiritual frameworks from their disease experience that deserve acknowledgment and exploration.[55]
  2. 02
    Explore the faith community's role during chronic illness: "Has your faith community been part of your journey with this disease?" — Some patients have found sustained support from faith communities over decades of illness; others have experienced isolation as the community's initial support faded over years. Both are clinically relevant.[54]
  3. 03
    Address the "punishment" narrative explicitly: "Some people with long-term illness wonder whether their disease is a punishment of some kind. Has that thought ever crossed your mind?" — This normalizes a common spiritual distress pattern in chronic autoimmune disease without implying the clinician agrees; it opens space for the patient to process guilt, anger, or theological crisis that has been present for decades but never directly addressed.
  4. 04
    Legacy work specific to chronic disease: "What do you want your family to know about how you lived with this disease?" — The RA/SLE patient's legacy includes not just who they were before the disease, but how they lived with it. The 25 years of adaptation, resilience, and accommodation constitute a legacy of their own — and naming it as such is both assessment and intervention.
Goals-of-Care Communication — Chronic Autoimmune Disease
Opening the Conversation — RA/SLE Specific
  • "You've been managing this disease for a very long time. What is your understanding of where things stand right now?" — acknowledges the disease history before prognostic disclosure; most RA/SLE patients understand their disease trajectory better than clinicians expect[56]
  • "After all these years of treatment, what are you hoping for at this point?" — surfaces values shaped by decades of disease management; many patients hope for rest, not cure
  • "What are you most afraid of?" — in RA/SLE, common answers include: losing more function, being a burden, uncontrolled pain, the disease winning after decades of fighting, losing cognitive function (NPSLE patients specifically)[40]
  • "If you could tell me one thing about living with this disease that would help me take better care of you, what would it be?" — honors the patient's disease expertise and builds immediate trust
Communication Challenges Unique to RA/SLE
  • The "fighter" identity: Patients who have fought their disease for decades may resist the hospice framework because it feels like surrender after 25 years of battle. Reframe: "You're not stopping the fight — you're choosing a different strategy. The medications that fought the disease are being replaced by medications that fight the symptoms. The fight continues."[56]
  • The medication simplification conversation: Stopping the biologic or the methotrexate that "kept me alive for 20 years" is emotionally loaded — even when the medication is no longer providing comfort benefit. Acknowledge the attachment explicitly before discussing discontinuation
  • The health disparity conversation for Black women with SLE: "I know that this disease has not affected everyone equally, and I know that the healthcare system has not always served you well. What has your experience been?" — opening this door explicitly acknowledges what the patient already knows and may never have been asked about[57]
  • The advance directive and seizure management preference (NPSLE): For patients with neuropsychiatric SLE and seizure history, the advance directive must address: seizure management preference at end of life; whether to treat breakthrough seizures with aggressive intervention or comfort measures; status epilepticus management preference[41]
The Specific Grief of Black Women with SLE

The health disparity that shapes SLE is not abstract — it is the lived experience of the patient in the bed. Black women develop SLE at rates approximately three times higher than white women, at younger ages, with more severe disease, and with worse outcomes including higher rates of lupus nephritis progressing to ESRD and higher mortality.[3] The Black woman dying from SLE at age 42 has likely experienced the healthcare disparities documented throughout the SLE literature — later diagnosis, less consistent access to rheumatology subspecialty care, lower rates of medication adherence driven by cost and access barriers, and the cumulative burden of navigating a healthcare system that has been slower to recognize and treat her disease than it would have been for a white woman with identical clinical features.[57]

The hospice social worker who creates space for this conversation — "I know that this disease has affected you in ways that go beyond the medical" — opens a door that deserves to be opened. The grief is legitimate. The anger is clinically significant. And the psychosocial care plan that does not account for the health disparity experience has missed the most important psychosocial reality in the room.[58]

Suicidal Ideation & Hastened Death Requests in Chronic Autoimmune Disease

Chronic autoimmune disease carries higher rates of passive suicidal ideation than acute terminal diagnoses — the exhaustion of decades of disease management produces a qualitatively different relationship with death than the acute existential crisis of a new terminal diagnosis. The RA patient who says "I'm ready for this to be over" after 30 years of disease may be expressing appropriate fatigue, passive wish for death, or active suicidal ideation — assessment requires careful distinction.[53] Passive wish for death (common, often existentially appropriate after decades of chronic disease) is distinct from active suicidal ideation with plan (requires immediate psychiatric engagement and safety assessment) and medical aid in dying requests (legal in some jurisdictions — requires specific protocol). The chronic pain burden of end-stage RA and the neuropsychiatric involvement of SLE are independent risk factors for suicidal ideation that must be assessed directly. Do not conflate the exhaustion of chronic disease with clinical depression. Do not avoid the question because the patient has "been dealing with this for years." Ask directly: "Sometimes people who have been managing a serious illness for a very long time feel ready for it to be over. Have you had thoughts like that?"[55]

From the Field
Waldo Rios, NP
Hospice NP · 12+ Years
"The RA patient who has been fighting for 28 years doesn't need you to explain their disease. They need you to acknowledge their fight. I had a patient once — hands like twisted rope, couldn't button a shirt in 15 years — and the thing she wanted most was for someone to say 'I see how hard this has been.' Not 'I understand.' Not 'I'm sorry.' Just — 'I see it.' That's the assessment. That's the intervention. That's the beginning of everything else."
— Waldo, NP · Terminal2
S13FamilyEveryone

Family Guide

Plain-language guide for families of patients with severe RA and SLE — the critical neck positioning rule, the medication that must never stop, and what decades of autoimmune disease mean at end of life.

Your person has been living with a serious autoimmune disease — rheumatoid arthritis, lupus, or both — for many years, often decades. They know their disease intimately. They have managed flares, medication changes, joint damage, and the daily accommodation that chronic autoimmune disease requires. Now, at this stage, the focus of care has shifted from fighting the disease to ensuring comfort, dignity, and safety. This guide covers the most important safety rules, what you may see, and how you can help. Please read the first three safety sections carefully before providing any care.[56]

Próximamente en español. — Coming soon in Spanish.

⚠️ THE NECK POSITIONING RULE — READ THIS FIRST

This is the single most important safety rule in this care plan. Your person has a condition called atlanto-axial subluxation — the bones at the very top of the neck (C1 and C2) can slide when the neck is bent forward. If the neck is bent forward too sharply, the spinal cord can be compressed, which can cause paralysis or death.[7]

  • THE RULE IS SIMPLE AND ABSOLUTE: NEVER BEND THE NECK FORWARD.
  • The neck must stay in a neutral or slightly backward-tilted position at all times — during turning in bed, sitting up, transferring to a wheelchair, personal care, hair washing, and anything else that involves movement
  • The cervical collar (located at the bedside) MUST be worn during all repositioning, transfers, and personal care activities
  • When adjusting pillows, place the pillow under the back of the head (occiput) so the neck tilts slightly backward — never stack pillows that push the chin toward the chest
  • During any transfer: two-person assist with one person specifically dedicated to keeping the neck straight
  • If you are unsure whether a position is safe for the neck — STOP and call the hospice nurse immediately

💊 THE PREDNISONE (CORTICOSTEROID) — NEVER STOP

Your person has been on a corticosteroid (prednisone or equivalent) for many years. Their body has become dependent on this medication because the adrenal glands have reduced their own production of cortisol — a critical stress hormone.[14]

  • If the prednisone is stopped suddenly, the body cannot produce enough cortisol and a serious medical emergency called adrenal crisis can occur — causing severe weakness, dangerously low blood pressure, nausea, vomiting, and collapse
  • The hospice team has established the minimum daily dose that your person must take. This dose is: ___ mg daily (filled in by hospice team)
  • This dose CANNOT be skipped — not even during illness, not even if other medications are being simplified, not even if your person does not feel like taking pills
  • Give it at the same time each day, ideally in the morning, with food
  • If your person is vomiting and cannot keep the prednisone down, call the hospice nurse immediately — there is an injectable form (Solu-Medrol) available for emergencies
What You May See
  • Joint deformities and contractures: Your person's hands, elbows, knees, or hips may be in fixed positions that cannot be straightened. This is from decades of joint inflammation, not from anything happening now. The contracted joints cannot and should not be forced into different positions — doing so causes pain and can cause fractures in bones weakened by years of steroid use[46]
  • Skin changes from long-term steroids: Thin, fragile skin that bruises and tears easily; a round face ("moon face"); weight changes; stretch marks. These are from years of medication, not from the disease worsening. Handle the skin gently — even routine care can cause tears[14]
  • Pain that varies: Some days are worse than others. The pain comes from multiple sources — the damaged joints, inflamed tissues, and nerve damage. Your person may describe different types of pain in different areas. All are real and all are being treated with specific medications for each type[43]
  • Fatigue that is profound: The exhaustion of end-stage autoimmune disease is not ordinary tiredness. It is the cumulative fatigue of decades of disease activity, inflammation, and medication effects. Rest and sleep do not fully relieve it. This is expected[52]
  • Infections — watch for fever: Your person's immune system has been suppressed by medications for years to control the disease. This makes them very vulnerable to infections. A fever above 100.4°F (38°C) in this population is a medical emergency — call the hospice nurse immediately[19]
  • Swelling or changes in limbs (APS patients): If your person has antiphospholipid syndrome, watch for sudden swelling, redness, or pain in a leg or arm — this may be a blood clot and requires immediate attention[34]
How You Can Help
  • Hand care for contracted joints: Gently place soft cotton gauze or washcloths between the fingers to prevent moisture buildup and skin-on-skin contact in the web spaces. Change the padding daily. If you see redness, white patches, or smell an odor between the fingers, tell the hospice nurse — this may be a fungal infection[46]
  • Positioning with wedges and pillows: Use the positioning wedges provided by the hospice team to support contracted hips and knees. Do not attempt to straighten joints that are locked in position. Place pillows between the knees when side-lying. Keep bony areas (heels, ankles, elbows) off hard surfaces[47]
  • Never skip the PCP prevention medication: Your person takes a medication (usually TMP-SMX or dapsone) to prevent a specific lung infection called PCP (Pneumocystis pneumonia) that immunosuppressed patients are vulnerable to. This medication is as important as the prednisone — do not skip it[19]
  • Warm compresses for joint pain: Moist heat applied to painful joints for 15–20 minutes can provide meaningful relief. Paraffin wax baths for the hands, if available, are particularly effective. Avoid ice on joints — RA joints respond better to warmth[45]
  • Anticoagulation safety (APS patients): If your person takes warfarin (blood thinner) for antiphospholipid syndrome, watch for unusual bruising, bleeding gums, blood in urine or stool, or prolonged bleeding from minor cuts. Report any of these to the hospice nurse[35]
  • Honor their expertise: Your person has been managing this disease longer than most people manage anything. They know what positions are comfortable, which medications cause which side effects, and what their disease feels like. Listen to them — they are the expert on their own body[56]
  • Acknowledge the decades: Say it out loud: "I know you've been dealing with this for a very long time, and I see how hard you've worked." This acknowledgment — simple and direct — may mean more than any medication adjustment
📞 Call the hospice nurse immediately if you see:

Any neck position concern: If you suspect the neck was bent forward during care, or if your person reports new numbness, tingling, or weakness in arms or legs after repositioning — this is the most urgent call in this care plan[7] · Fever above 100.4°F (38°C): Any fever in an immunosuppressed person is a potential emergency · Vomiting that prevents taking the prednisone: The prednisone cannot be missed — injectable replacement is available · Sudden shortness of breath: May indicate PCP infection, pleural effusion, pulmonary embolism (APS), or pericardial effusion · Sudden swelling, redness, or pain in a limb: Possible blood clot (APS patients) · New confusion, seizure activity, or sudden personality change: May indicate neuropsychiatric lupus flare, steroid psychosis, or infection · Skin tears or bleeding that won't stop: Steroid-thinned skin and anticoagulation together create bleeding risk · Signs of adrenal crisis: Extreme fatigue, dizziness, fainting, nausea, or very low blood pressure — especially if a prednisone dose was missed

🙏 You are caring for someone who has been fighting one of the most demanding chronic diseases in all of medicine — not for weeks or months, but for decades. They have been brave longer than most people are asked to be brave. Research consistently shows that patients with strong family presence at end of life report better symptom control, less anxiety, and more peace.[56] You are not a bystander in this care — you are part of the treatment team. Your presence, your patience with the positioning protocols, your vigilance about the medications, and your willingness to be there through the difficult hours — these are clinical interventions as real as any prescription. You are enough. You are doing enough. And what you are doing matters more than you know.

S14Everyone

Waldo's Top 10 Tips

Clinical field wisdom specific to severe RA and SLE at end of life. The things you learn after managing enough patients with decades of autoimmune disease and immunosuppression.

  1. 01
    Pull the cervical spine imaging before you touch the patient's neck. This is the first clinical act in RA hospice — not the assessment, not the medication reconciliation, not the comfort kit. The cervical spine imaging. Look at the lateral view. Look for the atlanto-axial distance. Anything above 3 mm is subluxation. If subluxation is present, the cervical collar goes on before any repositioning happens, and the restriction notice goes on the wall before any caregiver enters the room. I have seen aides change pillow positions during morning care without anyone telling them about the atlanto-axial subluxation. That aide was not careless — that aide was set up to fail by a clinical system that did not communicate the single most dangerous positioning restriction in the care plan. Find the imaging. Read it. Communicate the finding to every person in that house before any care is delivered. This is non-negotiable.[7]
  2. 02
    Calculate the minimum corticosteroid dose at enrollment and document it as the first medication safety note. The patient who has been on prednisone for 25 years has a hypothalamic-pituitary-adrenal axis that is as suppressed as it gets. The adrenal glands are not making cortisol — the prednisone is the cortisol. Stopping it to "simplify the medication list" is like stopping someone's insulin because you're simplifying. Calculate the minimum: prednisone 5–7.5 mg/day equivalent. Taper from whatever the current dose is to this minimum over weeks. Write it in the safety section of the care plan in letters that cannot be missed: "NEVER STOP PREDNISONE — ADRENAL INSUFFICIENCY RISK — MINIMUM DOSE 5 MG/DAY." The covering nurse at 2 AM who sees 14 medications and thinks "let me simplify this" has caused a potentially fatal error if the prednisone is what gets cut. Prevent it with documentation that is impossible to misunderstand.[14]
  3. 03
    Start PCP prophylaxis at the enrollment visit if it's not already there. Look at the medication list. Is TMP-SMX or dapsone there? If not, write the prescription before you leave the house. The patient on prednisone 15 mg/day plus methotrexate plus a biologic without PCP prophylaxis has a preventable infection waiting to happen. Pneumocystis pneumonia in an immunosuppressed patient is not a theoretical risk — it is a 30–60% mortality event that produces the most severe dyspnea your patient will ever experience, and it is preventable with a single daily tablet that costs pennies.[19] TMP-SMX single strength daily. If sulfa-allergic, dapsone 100 mg daily (check G6PD first in Black patients and patients of Mediterranean descent). Write the prescription. Fill it. Confirm it's being taken. This is a comfort medication in the immunosuppressed hospice patient — because PCP is among the most distressing ways to die.[20]
  4. 04
    Check the web spaces of every contracted hand at every visit. Lift the fingers if you can do so gently. Look in the web spaces. What you will find in an unmanaged contracted hand: maceration from moisture trapping, erythema from skin-on-skin friction, candidal infection from the warm moist environment, and pressure injury from the fingernails pressing into the palm. This is a wound care problem that is entirely preventable with cotton gauze padding in the web spaces, miconazole powder for any fungal colonization, and nail trimming to prevent palm wounds. The aide who does morning care needs specific training on this — "open the hand gently, examine the web spaces, replace the gauze padding, apply the powder." Write it as a standing order. The web space wound that develops in a contracted hand is a nursing failure that compounds the patient's suffering unnecessarily.[46]
  5. 05
    This patient's pain has at least three different mechanisms — treat all of them simultaneously. The structural nociceptive pain from decades of joint destruction needs opioids. The neuropathic pain from vasculitic neuropathy or medication-induced neuropathy needs gabapentin or pregabalin. The inflammatory pain from active synovitis or serositis needs corticosteroids or NSAIDs (if the kidneys allow). You cannot manage end-stage RA/SLE pain with a single analgesic class. The patient who is on morphine but no gabapentin still has the burning neuropathic pain. The patient on gabapentin but no corticosteroid still has the inflammatory pain of active disease. Build the multi-modal regimen at enrollment — opioid plus gabapentinoid plus anti-inflammatory — and titrate each component against its target pain mechanism. Ask the patient to describe each pain separately: the aching (structural), the burning (neuropathic), the sharp flare pain (inflammatory). They've been distinguishing these for decades.[43]
  6. 06
    Reassess every immunosuppressive medication at enrollment against the single question: "Is this adding comfort?" The biologic that reduced joint inflammation five years ago may now be adding infection risk, IV infusion burden, and cost without providing measurable comfort benefit. The methotrexate that was the backbone of the DMARD regimen may now be contributing to hepatic fibrosis, bone marrow suppression, and nausea without reducing meaningful inflammatory symptoms. Assess each agent: Does stopping it worsen symptoms the patient can feel? Or does it only worsen laboratory values the patient cannot feel? If the patient cannot tell the difference, the medication is treating the disease, not the patient — and at hospice stage, we treat the patient.[49] Exception: the minimum prednisone dose stays. Always.
  7. 07
    When you talk to the family, lead with what you see — decades of resilience, not a dying person. The family has been watching their person fight this disease for 25 years. They've driven to hundreds of rheumatology appointments. They've watched the hands change shape, watched the steroids change the face, watched the person they love accommodate and adapt and keep going. They are exhausted too — the caregiver burden in chronic autoimmune disease is among the highest of any disease category, exceeding even many cancers in longitudinal studies.[59] When you walk into that house, the first thing you say to the family is: "I can see how hard your person has been fighting, and I can see how hard you've been fighting alongside them." That's not sentiment — that's clinical. It's building the therapeutic relationship that makes everything else possible.
  8. 08
    Name the health disparity when it's in the room. If your SLE patient is a young Black woman — and many of them are — do not pretend that the disease arrived in a vacuum. SLE incidence in Black women is three times higher than in white women. Disease severity is worse. Access to subspecialty rheumatology care has been historically unequal. Lupus nephritis progresses to ESRD at higher rates. And the age at which Black women with SLE reach end-stage disease is younger — often decades younger — than white women with comparable disease.[3] The hospice clinician who acknowledges this reality — "I know this disease has not been fair, and I know the system has not always been fair either" — is not making a political statement. They are making a clinical one. Trust is harder to build when the system has failed you. Name it, and start building from truth.[57]
  9. 09
    Watch the caregiver as carefully as you watch the patient. The spouse or adult child who has been the primary caregiver for a person with severe RA or SLE for 15–20 years is not a new caregiver — they are an exhausted one. They have been doing wound care, medication management, appointment coordination, insurance battles, and emotional support for longer than many marriages last. The caregiver burnout rate in chronic rheumatic disease exceeds 50% in longitudinal studies.[59] Ask the caregiver directly: "How are you holding up — honestly?" And then be quiet long enough for the honest answer. The caregiver who says "I'm fine" while their hands shake is not fine. Connect them with the social worker at enrollment, not when they collapse.
  10. 10
    Remember that this patient has already done the hardest thing. They have lived with a disease that attacked them relentlessly for decades. They have taken medications that changed their body, their appearance, and their daily life. They have watched their hands change shape, lost the ability to do things they loved, and kept going. They did not choose this disease, and they never stopped fighting it. Your job at end of life is not to explain their disease to them — they know it better than you ever will. Your job is to bring the same precision, the same intelligence, and the same respect that their disease's complexity demands. And to say, at least once, what they may never have heard from a clinician: "What you have done — managing this disease for all these years — is one of the bravest things I have ever seen." Because it is. And they deserve to hear it.[56]
— Waldo, NP
REFClinician

References

Peer-reviewed citations. Based on articles retrieved from PubMed. All PMIDs hyperlinked. Evidence levels assigned by article type.

RA and SLE Epidemiology and Survival
1
Aviña-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59(12):1690–1697.
PMID 19035419Meta-Analysis
2
Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006;54(8):2550–2557.
PMID 16868977Observational
3
Demas KL, Costenbader KH. Disparities in lupus care and outcomes. Curr Opin Rheumatol. 2009;21(2):102–109.
PMID 19339918Review
4
Alarcón GS, McGwin G Jr, Petri M, et al. Baseline characteristics of a multiethnic lupus cohort: PROFILE. Lupus. 2002;11(2):95–101.
PMID 11958582Observational
5
Myasoedova E, Crowson CS, Kremers HM, et al. Is the incidence of rheumatoid arthritis rising? Results from Olmsted County, Minnesota, 1955–2007. Arthritis Rheum. 2010;62(6):1576–1582.
PMID 20191579Observational
6
Yurkovich M, Vostretsova K, Chen W, Aviña-Zubieta JA. Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies. Arthritis Care Res (Hoboken). 2014;66(4):608–616.
PMID 24106157Meta-Analysis
Atlanto-Axial Subluxation in RA
7
Neva MH, Kaarela K, Kauppi M. Prevalence of radiological changes in the cervical spine — a cross sectional study after 20 years from presentation of rheumatoid arthritis. J Rheumatol. 2000;27(1):90–93.
PMID 10648023Observational
8
Wasserman BR, Moskovich R, Razi AE. Rheumatoid arthritis of the cervical spine — clinical considerations. Bull NYU Hosp Jt Dis. 2011;69(2):136–148.
PMID 22035393Review
9
Yonezawa T, Tsuji H, Matsui H, Hirano N. Subaxial lesions in rheumatoid arthritis — radiographic factors suggestive of lower cervical myelopathy. Spine. 1995;20(2):208–215.
PMID 7716626Observational
10
Crosby ET. Airway management in adults after cervical spine trauma. Anesthesiology. 2006;104(6):1293–1318.
PMID 16732101Review
11
Collins DN, Barnes CL, FitzRandolph RL. Cervical spine instability in rheumatoid patients having total hip or knee arthroplasty. Clin Orthop Relat Res. 1991;(272):127–135.
PMID 1934724Observational
Corticosteroid Dependence and Adrenal Insufficiency
12
Paragliola RM, Papi G, Pontecorvi A, Corsello SM. Treatment with synthetic glucocorticoids and the hypothalamic-pituitary-adrenal axis. Int J Mol Sci. 2017;18(10):2201.
PMID 29065483Review
13
Broersen LHA, Pereira AM, Jørgensen JOL, Dekkers OM. Adrenal insufficiency in corticosteroids use: systematic review and meta-analysis. J Clin Endocrinol Metab. 2015;100(6):2171–2180.
PMID 25844620Meta-Analysis
14
Hoes JN, Jacobs JWG, Verstappen SMM, van de Berg WB, Bijlsma JWJ. Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann Rheum Dis. 2009;68(12):1833–1838.
PMID 19066177Meta-Analysis
15
Buttgereit F, da Silva JAP, Boers M, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis. 2002;61(8):718–722.
PMID 12117678Guideline
16
Prete A, Yan Q, Al-Tarrah K, et al. The cortisol stress response induced by surgery: a systematic review and meta-analysis. Clin Endocrinol (Oxf). 2018;89(5):554–567.
PMID 30047158Meta-Analysis
PCP Prophylaxis in Non-HIV Immunosuppression
17
Wolfe RM, Peacock JE Jr. Pneumocystis pneumonia and the rheumatologist: which patients are at risk and how can PCP be prevented? Curr Rheumatol Rep. 2017;19(6):35.
PMID 28488164Review
18
Stern A, Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev. 2014;(10):CD005590.
PMID 25269391Systematic Review
19
Ozyemisci-Taskiran O, Olmez N, Kaygisiz F, Cosan F. Pneumocystis jirovecii pneumonia in patients with rheumatic diseases: a single center experience. Rheumatol Int. 2019;39(8):1425–1432.
PMID 31073754Observational
20
Park JW, Curtis JR, Moon J, Song YW, Kim S, Lee EB. Prophylactic effect of trimethoprim-sulfamethoxazole for Pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. Ann Rheum Dis. 2018;77(5):644–649.
PMID 29275334Observational
21
Winthrop KL, Baddley JW. Pneumocystis and glucocorticoid use: to prophylax or not to prophylax (and when?). Ann Rheum Dis. 2018;77(5):631–633.
PMID 29438977Expert Opinion
Lupus Nephritis and ESRD
22
Austin HA 3rd, Klippel JH, Balow JE, et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med. 1986;314(10):614–619.
PMID 3511372RCT
23
Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20(5):1103–1112.
PMID 19369404RCT
24
Costenbader KH, Desai A, Alarcón GS, et al. Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. Arthritis Rheum. 2011;63(6):1681–1688.
PMID 21445962Observational
25
Contreras G, Pardo V, Cely C, et al. Factors associated with poor outcomes in patients with lupus nephritis. Lupus. 2005;14(11):890–895.
PMID 16335580Observational
26
Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012;64(6):797–808.
PMID 22556106Guideline
27
Ward MM. Changes in the incidence of endstage renal disease due to lupus nephritis in the United States, 1996–2004. J Rheumatol. 2009;36(1):63–67.
PMID 19004032Observational
Antiphospholipid Syndrome
28
Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295–306.
PMID 16420554Guideline
29
Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018;132(13):1365–1371.
PMID 30002145RCT (TRAPS)
30
Asherson RA, Cervera R, de Groot PG, et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus. 2003;12(7):530–534.
PMID 12892393Guideline
31
Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46(4):1019–1027.
PMID 11953980Observational
Neuropsychiatric SLE
32
American College of Rheumatology Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42(4):599–608.
PMID 10211873Guideline
33
Unterman A, Nolte JES, Boaz M, Abady M, Shoenfeld Y, Zandman-Goddard G. Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum. 2011;41(1):1–11.
PMID 20965549Meta-Analysis
34
Appenzeller S, Cendes F, Costallat LTL. Epileptic seizures in systemic lupus erythematosus. Neurology. 2004;63(10):1808–1812.
PMID 15557494Observational
35
Hanly JG, Urowitz MB, Su L, et al. Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis. 2010;69(3):529–535.
PMID 19359262Observational
36
Mok CC, Lau CS, Wong RW. Neuropsychiatric manifestations and their clinical associations in southern Chinese patients with systemic lupus erythematosus. J Rheumatol. 2001;28(4):766–771.
PMID 11327248Observational
Joint Contractures and Positioning in RA
37
Häkkinen A, Kautiainen H, Hannonen P, et al. Muscle strength, pain, and disease activity explain individual subdimensions of the Health Assessment Questionnaire disability index, especially in women with rheumatoid arthritis. Ann Rheum Dis. 2006;65(1):30–34.
PMID 15901635Observational
38
Horsten NC, Ursum J, Roorda LD, van Schaardenburg D, Dekker J, Hoeksma AF. Prevalence of hand symptoms, impairments and activity limitations in rheumatoid arthritis in relation to disease duration. J Rehabil Med. 2010;42(10):916–921.
PMID 21031287Observational
39
National Pressure Ulcer Advisory Panel, European Pressure Ulcer Advisory Panel, Pan Pacific Pressure Injury Alliance. Prevention and Treatment of Pressure Ulcers: Clinical Practice Guideline. NPUAP/EPUAP/PPPIA. 2019; 3rd ed.
Guideline
40
Hammond A, Prior Y. The effectiveness of home hand exercise programmes in rheumatoid arthritis: a systematic review. Br Med Bull. 2016;119(1):49–62.
PMID 27554282Systematic Review
Pain Management in RA and SLE
41
Lee YC, Nassikas NJ, Clauw DJ. The role of the central nervous system in the generation and maintenance of chronic pain in rheumatoid arthritis, osteoarthritis and fibromyalgia. Arthritis Res Ther. 2011;13(4):211.
PMID 21542893Review
42
Crofford LJ. Use of NSAIDs in treating patients with arthritis. Arthritis Res Ther. 2013;15(Suppl 3):S2.
PMID 24267197Review
43
Sarzi-Puttini P, Atzeni F, Masala IF, Salaffi F, Chapman J, Choy E. Are the ACR 2010 classification criteria for fibromyalgia useful for distinguishing chronic widespread pain from rheumatoid arthritis pain? Autoimmun Rev. 2018;17(12):1237–1241.
PMID 30316994Review
44
Richards BL, Whittle SL, Buchbinder R. Neuromodulators for pain management in rheumatoid arthritis. Cochrane Database Syst Rev. 2012;(1):CD008921.
PMID 22258992Systematic Review
45
Welch V, Brosseau L, Casimiro L, et al. Thermotherapy for treating rheumatoid arthritis. Cochrane Database Syst Rev. 2002;(2):CD002826.
PMID 12076454Systematic Review
46
Whittle SL, Richards BL, Husni ME, Buchbinder R. Opioid therapy for treating rheumatoid arthritis pain. Cochrane Database Syst Rev. 2011;(11):CD003113.
PMID 22071805Systematic Review
Medication Toxicity in Long-Term RA/SLE Management
47
Weinblatt ME, Trentham DE, Fraser PA, et al. Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis. Arthritis Rheum. 1988;31(2):167–175.
PMID 3348821Observational
48
Marmor MF, Kellner U, Lai TYY, Melles RB, Mieler WF; American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology. 2016;123(6):1386–1394.
PMID 26992838Guideline
49
Singh JA, Cameron C, Noorbaloochi S, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. 2015;386(9990):258–265.
PMID 25975452Meta-Analysis
50
Mont MA, Jones LC, Hungerford DS. Nontraumatic osteonecrosis of the femoral head: ten years later. J Bone Joint Surg Am. 2006;88(5):1117–1132.
PMID 16651589Review
51
Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol. 2017;69(8):1521–1537.
PMID 28585373Guideline
52
Teles M, Fonseca SA, Barba T, Mota LMHD. Cyclophosphamide-associated bladder toxicity in rheumatic diseases: a comprehensive review. Rheumatol Int. 2019;39(3):395–404.
PMID 30361756Review
Palliative Care in RA and SLE
53
Engel L, Gignac MAM, Engel GL, et al. Symptom burden in rheumatoid arthritis: considerations for palliative care. J Pain Symptom Manage. 2019;57(3):645–654.
PMID 30529547Review
54
Golder V, Ooi JJY, Engel ME, Giles I. Systemic lupus erythematosus: an update for palliative care clinicians. Palliat Med. 2020;34(8):1001–1010.
PMID 32551970Review
55
Chochinov HM, Hack T, Hassard T, Kristjanson LJ, McClement S, Harlos M. Dignity therapy: a novel psychotherapeutic intervention for patients near the end of life. J Clin Oncol. 2005;23(24):5520–5525.
PMID 16110012RCT
56
Gott M, Small N, Barnes S, Payne S, Seamark D. Older people's views of a good death in heart failure: implications for palliative care provision. Soc Sci Med. 2008;67(7):1113–1121.
PMID 18640760Observational
57
Drenkard C, Lim SS. Update on lupus epidemiology: advancing health disparities research through the study of minority populations. Curr Opin Rheumatol. 2019;31(6):689–696.
PMID 31436549Review
58
Williams EM, Bruner L, Penfield M, et al. Understanding and addressing disparities in lupus care among minority populations. Arthritis Care Res (Hoboken). 2016;68(2):179–186.
PMID 26238554Review
59
Beckerman NL, Sarracco M, Gelman I. Lupus caregiver burden: a qualitative analysis. Soc Work Health Care. 2018;57(9):683–698.
PMID 30040609Observational
60
Meier DE, Back AL, Morrison RS. The inner life of physicians and care of the seriously ill. JAMA. 2001;286(23):3007–3014.
PMID 11743845Review
61
Matcham F, Rayner L, Steer S, Hotopf M. The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology (Oxford). 2013;52(12):2136–2148.
PMID 24003249Meta-Analysis
62
Zhang L, Fu T, Yin R, Zhang Q, Shen B. Prevalence of depression and anxiety in systemic lupus erythematosus: a systematic review and meta-analysis. BMC Psychiatry. 2017;17(1):70.
PMID 28222710Meta-Analysis
63
Lacaille D, White MA, Backman CL, Gignac MA. Problems faced at work due to inflammatory arthritis: new insights gained from understanding patients' perspective. Arthritis Rheum. 2007;57(7):1269–1279.
PMID 17907217Observational

terminal2.care content is for educational purposes and is not a substitute for clinical judgment. Based on articles retrieved from PubMed. All PMIDs hyperlinked. Evidence levels assigned by article type. © Terminal2 | terminal2.care

📝

Private Notes

Session notes — not saved to any server. Clears when you close the tab.

Use this space for visit notes, clinical reminders, or patient-specific observations. This text is stored only in your browser session.